Find Paid Research Studies in North Carolina

Browse Locations ... United States» ... North Carolina

Expanded Access to T-cell Depleted Haplo-Identical Stem Cells for Patients Receiving Haplo-Identical and Unrelated Cord Blood Transplants

Conditions: Hematologic Malignancies; Inborn Errors of Metabolism Disorders; Immune Deficiencies
Intervention: Biological: CliniMACS CD34 Reagent System
Sponsors: Duke University; Joanne Kurtzberg; Duke University; Miltenyi Biotec, Inc.
Available - verified June 2013
Multi-center, Randomized, Double-blind Efficacy and Safety of CD0271 0.3%/CD1579 2.5 % Topical Gel in Acne Vulgaris

Condition: Acne Vulgaris
Interventions: Drug: CD0271 0.3% / CD1579 2.5%; Drug: CD0271 0.1% / CD1579 2.5%; Drug: Topical Gel Vehicle
Sponsors: Galderma R&D; Galderma R&D
Not yet recruiting - verified June 2013
Identification of Herpes Simplex Virus (HSV) Shedding in the Female Genital Tract of Pregnant and Nonpregnant Women by GeneXpert PCR, Routine PCR, and Culture

Condition: Herpes Simplex Virus
Intervention: Device: Genexpert assay
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham
Not yet recruiting - verified June 2013
Study of Purified Vero Rabies Vaccine and Rabies Human Diploid Cell Vaccine in a Simulated Rabies Post-exposure Regimen

Condition: Rabies
Interventions: Biological: Purified Vero Rabies Vaccine (VRVg); Biological: Imovax® Rabies: inactivated rabies vaccine
Sponsors: Sanofi; Sanofi Pasteur, a Sanofi Company
Recruiting - verified June 2013
Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis

Condition: Bacterial Conjunctivitis
Interventions: Drug: Auriclosene Ophthalmic Solution; Drug: Vehicle Ophthalmic Solution
Sponsors: NovaBay Pharmaceuticals, Inc.; NovaBay Pharmaceuticals, Inc.
Not yet recruiting - verified June 2013
Traditional African Healing Ceremony in a U.S. Population

Conditions: Chronic Fatigue Syndrome; Anxiety; Depression; Cancer
Intervention: Behavioral: Movement to rhythm
Sponsors: Duke University; Duke University
Not yet recruiting - verified June 2013
Functional Movement Retraining After Hip Replacement

Condition: Arthrloplasty, Replacement, Hip
Intervention: Behavioral: Functional Movement Retraining
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs; Duke University
Not yet recruiting - verified June 2013
A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -304)

Condition: Plaque Psoriasis
Interventions: Drug: 000-0551 Lotion; Drug: Vehicle Lotion
Sponsors: Therapeutics, Inc.; Therapeutics, Inc.
Recruiting - verified June 2013
Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib

Condition: Breast Neoplasms
Interventions: Drug: Trastuzumab; Drug: pertuzumab; Drug: lapatinib
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; Genentech; Susan G. Komen Breast Cancer Foundation; GlaxoSmithKline
Not yet recruiting - verified June 2013
Study of Ixekizumab in Participants With Active Ankylosing Spondylitis (AS)

Condition: Spondylitis, Ankylosing
Interventions: Drug: Ixekizumab; Drug: Placebo; Drug: Adalimumab
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Not yet recruiting - verified June 2013
Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia

Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Promyelocytic Leukemia (M3); Childhood Acute Promyelocytic Leukemia (M3); Recurrent Adult Acute Myeloid Leukemia; Recurrent Childhood Acute Myeloid Leukemia
Interventions: Drug: gemtuzumab ozogamicin; Other: laboratory biomarker analysis
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Not yet recruiting - verified May 2013
International Pediatric Fungal Network

Condition: Pediatric Invasive Candidiasis
Intervention: Drug: Observational antifungal therapy
Sponsors: Duke University; Duke University; Children's Hospital of Philadelphia
Not yet recruiting - verified May 2013
Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer

Conditions: Ductal Breast Carcinoma in Situ; Lobular Breast Carcinoma in Situ; Male Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer
Interventions: Dietary Supplement: omega-3 fatty acid; Other: placebo; Other: laboratory biomarker analysis
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Not yet recruiting - verified May 2013
Bioelectrical Impedance Measurement for Predicting Treatment Outcome in Patients With Newly Diagnosed Acute Leukemia

Conditions: Acute Undifferentiated Leukemia; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Mast Cell Leukemia; Myeloid/NK-cell Acute Leukemia; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Adult Acute Myeloid Leukemia
Intervention: Procedure: bioelectric impedance analysis
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Not yet recruiting - verified May 2013
Brief Intervention to Create Smoke-Free Homes Policies in Low-Income Households: North Carolina Effectiveness Trial

Condition: Chronic Disease
Intervention: Behavioral: Educational print materials and coaching call
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; National Cancer Institute (NCI); Emory University; The University of Texas Health Science Center, Houston; Washington University in St. Louis
Not yet recruiting - verified May 2013
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder

Condition: Overactive Bladder
Interventions: Drug: dexmecamylamine; Drug: Placebo
Sponsors: Targacept Inc.; Targacept Inc.
Recruiting - verified June 2013
DISKUS vs. ELLIPTA Device Preference Study in Chronic Obstructive Pulmonary Disease (COPD)

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Device: ELLIPTA; Device: DISKUS
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified May 2013
ACE-Inhibitor Effects on Total Hip and Knee Arthroplasty Patients

Condition: Adverse Effects of Angiotensin-converting-enzyme Inhibitors
Interventions: Other: Cessation group; Other: Continuation group
Sponsors: Duke University; Duke University
Not yet recruiting - verified May 2013
A Study of Tadalafil for Duchenne Muscular Dystrophy

Condition: Muscular Dystrophy, Duchenne
Interventions: Drug: Tadalafil; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Not yet recruiting - verified June 2013
Microfinance and Health Intervention Trial for Youth in Dar es Salaam, Tanzania

Conditions: Sexually Transmitted Infections; Gender Based Violence Perpetration
Intervention: Behavioral: Microfinance and Health Leadership
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; National Institute of Mental Health (NIMH)
Not yet recruiting - verified May 2013
Effect of Lung Cancer Diagnoses on Family Behaviors

Conditions: Lung Cancer; Blood Relatives of Patient w/Lung Cancer; Cigarette Smokers
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Human Genome Research Institute (NHGRI)
Recruiting - verified December 2012
Peanut Oral Immunotherapy in Children

Condition: Peanut Hypersensitivity
Intervention: Biological: Peanut Oral Immunotherapy
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); Immune Tolerance Network (ITN)
Recruiting - verified May 2013
A Prospective, Observational Study of Pregnancy Outcomes Among Women Exposed to Truvada for PrEP Indication

Condition: HIV Infection
Intervention:
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013
Early Mobility for the Critically Injured Burn Patient

Condition: Critically Injured Burn Patients
Intervention: Other: Standardized Rehabilitation Therapy
Sponsors: Wake Forest University; Peter E. Morris; Department of Defense; Washington University School of Medicine; University of North Carolina, Chapel Hill
Recruiting - verified May 2013
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML

Conditions: Lymphoblastic Leukemia, Acute, Childhood; Myelogenous Leukemia, Acute, Childhood
Interventions: Drug: Azacitidine; Drug: Fludarabine; Drug: Cytarabine
Sponsors: Therapeutic Advances in Childhood Leukemia Consortium; Therapeutic Advances in Childhood Leukemia Consortium; Gateway for Cancer Research; USC/Norris Comprehensive Cancer Center
Not yet recruiting - verified May 2013
Study of Dupilumab (REGN668/ SAR231893) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

Condition: Atopic Dermatitis
Interventions: Drug: Dupilumab (REGN668/ SAR231893); Drug: Placebo
Sponsors: Regeneron Pharmaceuticals; Regeneron Pharmaceuticals; Sanofi
Recruiting - verified May 2013
A Prospective Evaluation of the Effect of Curcumin on Dose Limiting Toxicity and Pharmacokinetics of Irinotecan in Colorectal Cancer

Condition: Advanced Colorectal Cancer
Interventions: Dietary Supplement: curcumin; Drug: Irinotecan
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center
Not yet recruiting - verified May 2013
Improved Patient Handoffs to Prevent Sentinel Events

Conditions: Health Care Quality,; Access and Evaluation
Intervention: Other: Structured Sign Out Form
Sponsors: Duke University; Duke University
Not yet recruiting - verified May 2013
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 1)

Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: GFF MDI; Drug: GP MDI; Drug: FF MDI; Drug: Open-label tiotropium bromide inhalation powder; Drug: Placebo MDI
Sponsors: Pearl Therapeutics, Inc.; Pearl Therapeutics, Inc.
Recruiting - verified June 2013
Phase 2 Study of SOF+GS-5816 in Treatment Naive Subjects With Chronic HCV

Condition: Hepatitis C
Intervention: Drug: SOF in combination with GS-5816
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified June 2013
Safety and Efficacy of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)

Condition: Chronic Hepatitis C Virus
Interventions: Drug: Sofosbuvir/Ledipasvir 400/90 mg; Drug: Ribavirin
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013
Open Label Study of Long Term Evaluation Against LDL-C Trial-2

Condition: Hyperlipidemia and Mixed Dyslipidemia
Interventions: Drug: AMG 145 and standard of care; Other: Standard of care
Sponsors: Amgen; Amgen
Recruiting - verified June 2013
A Study Of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Condition: Non-Small Cell Lung Cancer
Intervention: Drug: MPDL3280A
Sponsors: Genentech; Genentech
Recruiting - verified May 2013
CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Subjects With Type 1 Diabetes (T1DM)

Condition: Type 1 Diabetes Mellitus
Interventions: Drug: Commercial Hylenex® recombinant (hyaluronidase human injection); Drug: Pre-commercial formulation of Hylenex recombinant (hyaluronidase human injection); Procedure: Preadministration of commercial Hylenex® recombinant (hyaluronidase human injection); Procedure: Preadministration of pre-commercial Hylenex recombinant (hyaluronidase human injection); Device: Continuous Subcutaneous Insulin Infusion (CSII) via insulin infusion pumps
Sponsors: Halozyme Therapeutics; Halozyme Therapeutics
Recruiting - verified June 2013
A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies

Condition: Malignant Melanoma, Neoplasms
Interventions: Drug: vemurafenib; Drug: tizanidine
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified June 2013
Study to Evaluate Safety & Efficacy of WC3011 in Postmenopausal Women With Dyspareunia

Condition: Vulvovaginal Atrophy
Interventions: Drug: Estradiol Vaginal Gel; Drug: Vehicle
Sponsors: Warner Chilcott; Warner Chilcott
Recruiting - verified June 2013
A Dose-Optimization Study for the Initial Treatment of Dysplastic Barrett's Esophagus With trūFreeze™ Spray Cryotherapy

Condition: Barrett's Esophagus
Intervention: Device: trūFreeze™ Spray Cryotherapy
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; CSA Medical, Inc.
Recruiting - verified June 2013
A Phase 2, Multi-center Study to Evaluate the Efficacy and Safety of ONO-2952 in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

Condition: Irritable Bowel Syndrome (IBS)
Intervention: Drug: ONO-2952
Sponsors: Ono Pharmaceutical Co. Ltd; Ono Pharma USA Inc
Recruiting - verified May 2013
Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

Condition: Multiple Myeloma
Intervention:
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AbbVie
Recruiting - verified June 2013
Randomized Endo-Vein Graft Prospective

Condition: Coronary Artery Bypass Grafting
Intervention: Procedure: Vein Harvesting Procedures
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Not yet recruiting - verified June 2013
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD

Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: QVA149; Drug: fluticasone/salmeterol
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified June 2013
A Phase 2/3 Open-label Extension Study to Evaluate Long-Term Safety and Efficacy With VX-509 in Subjects With Rheumatoid Arthritis

Condition: Rheumatoid Arthritis
Intervention: Drug: VX-509
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated
Recruiting - verified May 2013
An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Condition: Relapsed or Refractory Mantle Cell Lymphoma
Intervention: Drug: Ibrutinib
Sponsors: Janssen Biotech, Inc.; Janssen Biotech, Inc.; Pharmacyclics
Recruiting - verified June 2013
A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years

Condition: Meningococcal Vaccine
Interventions: Biological: rLP2086; Biological: rLP2086; Biological: rLP2086; Biological: Havrix (HAV); Biological: Saline
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
An Evaluation of PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis

Condition: Atopic Dermatitis
Interventions: Drug: PDI-192; Drug: Vehicle
Sponsors: PreCision Dermatology, Inc.; PreCision Dermatology, Inc.
Recruiting - verified June 2013
Safety, Tolerability and Efficacy Study of LiRIS® 400mg in Women With Interstitial Cystitis

Condition: Interstitial Cystitis
Interventions: Drug: LiRIS 400 mg; Other: LiRIS Placebo
Sponsors: TARIS Biomedical, Inc.; TARIS Biomedical, Inc.
Recruiting - verified June 2013
A Study of JNJ-38518168 in Symptomatic Adult Participants With Uncontrolled, Persistent Asthma

Condition: Asthma
Interventions: Drug: Placebo; Drug: JNJ-38518168
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Not yet recruiting - verified June 2013
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy

Conditions: Muscular Dystrophy, Duchenne; Muscular Dystrophies; Muscular Disorders, Atrophic; Muscular Diseases; Musculoskeletal Diseases; Neuromuscular Diseases; Nervous System Diseases; Genetic Diseases, X-Linked; Genetic Diseases, Inborn
Interventions: Drug: Ataluren; Drug: Placebo
Sponsors: PTC Therapeutics; PTC Therapeutics
Recruiting - verified April 2013
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease

Conditions: Inflammatory Bowel Disease (IBD); Primary Sclerosing Cholangitis (PSC); Colorectal Neoplasms; Colorectal Cancer
Intervention:
Sponsors: Exact Sciences Corporation; Exact Sciences Corporation
Recruiting - verified June 2013
Adductor Canal Block for Medial Compartment Knee Arthroplasty

Conditions: Postoperative Analgesia; Medial Unicompartmental Knee Arthroplasty
Interventions: Procedure: Adductor canal block; Procedure: Lumbar plexus block
Sponsors: Wake Forest University Baptist Medical Center; Wake Forest University Baptist Medical Center
Recruiting - verified May 2013
Open-Label Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Combination Single Tablet Regimen (STR) in Virologically-Suppressed, HIV-1 Positive Subjects

Conditions: HIV; HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide; Drug: E/C/F/TDF, EFV/FTC/TDF, ritonavir + atazanavir + FTC/TDF, or GS-9350 + atazanavir + FTC/TDF
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013
A Study Exploring Two Strategies of Rivaroxaban and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

Conditions: Atrial Fibrillation; Percutaneous Coronary Intervention
Interventions: Drug: rivaroxaban 2.5 mg; Drug: rivaroxaban 15 mg; Drug: rivaroxaban 10 mg; Drug: aspirin (ASA); Drug: vitamin K antagonist (VKA); Drug: clopidogrel; Drug: prasugrel; Drug: ticagrelor
Sponsors: Janssen Scientific Affairs, LLC; Janssen Scientific Affairs, LLC; Bayer Pharma AG
Recruiting - verified May 2013
A Study in Men With Low Testosterone to Measure the Effects of Testosterone Solution on Testosterone Levels, Sex Drive and Energy

Condition: Hypogonadism
Interventions: Drug: Testosterone Solution; Drug: Placebo Solution
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013
Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With Hematological Malignancies

Conditions: Hematological Malignancies; Acute Lymphoblastic Leukemia (ALL); Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome (MDS)
Intervention: Genetic: NiCord®
Sponsors: Gamida Cell ltd; Gamida Cell ltd
Recruiting - verified June 2013
Respicardia, Inc. Pivotal Trial of the remedē System

Conditions: Sleep Apnea, Central; Sleep Disordered Breathing; Heart Failure
Interventions: Device: Treatment Group (remede; phrenic nerve stimulation); Device: Control Group (Optimal Medical Therapy)
Sponsors: Respicardia, Inc.; Respicardia, Inc.
Recruiting - verified June 2013
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: TAK-700; Drug: Bicalutamide
Sponsors: Southwest Oncology Group; Southwest Oncology Group; Millennium Pharmaceuticals, Inc.; National Cancer Institute (NCI)
Recruiting - verified June 2013
Comparison Study of ISV-303 to Durasite Vehicle in Cataract Surgery Subjects

Condition: Cataract
Interventions: Drug: ISV-303; Other: DuraSite Vehicle
Sponsors: InSite Vision; InSite Vision
Recruiting - verified March 2013
Does Oral Micronized Progesterone Shorten Time of Symptoms From Concussion

Condition: Concussion
Intervention: Drug: Progesterone
Sponsors: Wake Forest University; Wake Forest University; American Medical Society for Sports Medicine (AMSSM) Foundation
Recruiting - verified June 2013
A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation (TRAFFIC)

Condition: Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
Interventions: Drug: Ivacaftor; Drug: Lumacaftor; Drug: Ivacaftor Placebo; Drug: Lumacaftor Placebo
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated
Recruiting - verified June 2013
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection

Condition: Chronic Hepatitis C Infection
Interventions: Drug: ABT-450/r/ABT-267; Drug: ABT-333; Drug: Ribavirin; Drug: Placebo for Ribavirin
Sponsors: AbbVie; AbbVie
Recruiting - verified May 2013
Edoxaban in Peripheral Arterial Disease

Condition: Peripheral Arterial Disease
Interventions: Drug: edoxaban; Drug: Clopidogrel; Drug: Aspirin
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.; UMC Utrecht
Recruiting - verified June 2013
A Clinical Evaluation Of The Safety Of Baclofen Er Capsules (Grs) When Administered Once Daily To Subjects With Spasticity Due To Multiple Sclerosis (Ms): An Open Label, Long Term, Safety Trial

Condition: Spasticity
Intervention: Drug: Baclofen
Sponsors: Sun Pharma Advanced Research Company Limited; Sun Pharma Advanced Research Company Limited
Recruiting - verified April 2013
MARLINA : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: Linagliptin 5mg
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified June 2013
A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes

Conditions: Type 2 Diabetes; Comparative Effectiveness of Glycemia-lowering Medications
Interventions: Drug: Sulfonylurea (glimepiride); Drug: DPP-4 inhibitor (sitagliptin); Drug: GLP-1 receptor agonist (liraglutide); Drug: Insulin (glargine)
Sponsors: GRADE Study Group; GRADE Study Group; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Becton, Dickinson and Company; Bristol-Myers Squibb; Merck; Novo Nordisk; Hoffmann-La Roche; Sanofi
Recruiting - verified June 2013
A Study of RoActemra/Actemra (Tocilizumab) in Patients With Giant Cell Arteritis

Condition: Giant Cell Arteritis
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: tocilizumab [RoActemra/Actemra]; Drug: tocilizumab placebo; Drug: prednisone; Drug: prednisone placebo; Drug: tocilizumab [RoActemra/Actemra]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified June 2013
Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets for Moderate to Severe Chronic Low Back Pain

Condition: Low Back Pain
Interventions: Drug: Hydrocodone bitartrate extended-release tablets; Drug: Matching placebo
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Recruiting - verified May 2013
20120230: Assess the Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease on Hemodialysis

Condition: Hyperparathyroidism, Secondary
Interventions: Drug: AMG 416; Drug: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified June 2013
Open-Label Long-Term Safety and Efficacy Study of Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Subjects With Moderate to Severe Essential Hypertension

Condition: Hypertension
Interventions: Drug: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106); Drug: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106); Drug: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106); Drug: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
Sponsors: Bayer; Bayer
Recruiting - verified May 2013
Prevalence of Dysplasia of the Gastric Cardia

Conditions: Barrett's Esophagus; Intestinal Metaplasia; Intramucosal Adenocarcinoma
Intervention:
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; CSA Medical, Inc.
Recruiting - verified June 2013
Study of Meloxicam Capsules to Treat Osteoarthritis Pain

Condition: Osteoarthritis
Interventions: Drug: Meloxicam Test Capsules; Drug: Meloxicam Test Capsules; Drug: Placebo Capsules
Sponsors: Iroko Pharmaceuticals, LLC; Iroko Pharmaceuticals, LLC
Recruiting - verified June 2013
A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis

Conditions: Amyloidosis; Systemic Light-Chain Amyloidosis
Interventions: Drug: Carfilzomib; Drug: Dexamethasone
Sponsors: Academic Myeloma Consortium; Academic Myeloma Consortium; Onyx Pharmaceuticals; CORE Science Solutions; Criterium Inc.
Recruiting - verified June 2013
20120229: Assess the Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease on Hemodialysis

Condition: Hyperparathyroidism, Secondary
Interventions: Drug: AMG 416; Drug: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified June 2013
A Twelve Week Safety and Efficacy Study in Rosacea

Condition: Papulopustular Rosacea
Interventions: Drug: omiganan; Drug: placebo
Sponsors: Cutanea Life Sciences, Inc.; Cutanea Life Sciences, Inc.
Recruiting - verified June 2013
Study of an Investigational Nasal Aerosol or Placebo in Children (Ages 4 to 11) With Perennial Allergic Rhinitis (PAR)

Condition: Allergic Rhinitis
Interventions: Drug: BDP Nasal Aerosol; Drug: Placebo
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Recruiting - verified May 2013
Trial to Evaluate The Efficacy Of Rotigotine on Parkinson's Disease-Associated Motor Symptoms And Apathy

Condition: Idiopathic Parkinson's Disease
Interventions: Drug: Rotigotine; Other: Placebo
Sponsors: UCB, Inc.; UCB BIOSCIENCES GmbH
Recruiting - verified May 2013
Armodafinil in Reducing Cancer-Related Fatigue in Patients With Glioblastoma Multiforme

Conditions: Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Fatigue
Interventions: Drug: armodafinil; Other: Placebo
Sponsors: Alliance for Clinical Oncology Trials; Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified January 2013
Safety and Pharmacokinetics of Raltegravir in HIV-1-Exposed Newborn Infants at High Risk of Acquiring HIV-1 Infection

Condition: HIV Infections
Intervention: Drug: Raltegravir
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified June 2013
A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma

Condition: Lymphoma
Intervention: Drug: PCI-32765 (Ibrutinib)
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharmacyclics
Recruiting - verified June 2013
A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma

Condition: Mantle Cell Lymphoma
Interventions: Drug: Bendamustine; Drug: Rituximab; Drug: Ibrutinib; Drug: Placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharmacyclics
Recruiting - verified June 2013
A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Cardiac Surgery

Condition: Acute Kidney Injury
Interventions: Drug: ABT-719; Drug: Placebo
Sponsors: AbbVie; AbbVie
Recruiting - verified May 2013
Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: BI 10773; Drug: BI 10773 Placebo; Drug: BI 10773 / BI 1356; Drug: BI 10773; Drug: BI 10773 / BI 1356; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773 / BI 1356 Placebo; Drug: BI 10773 / BI 1356 Placebo; Drug: BI 10773; Drug: BI 10773 / BI 1356 Placebo; Drug: BI 10773 Placebo; Drug: BI 10773; Drug: BI 10773 / BI 1356 Placebo
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified June 2013
Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis

Condition: Moderate to Severe Nail Psoriasis
Interventions: Biological: secukinumab 150 mg; Biological: secukinumab 300 mg; Biological: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified June 2013
Study of Human Regular U-500 Insulin in Adult Participants With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Intervention: Drug: Human Regular U-500 Insulin
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013
Limb Girdle Muscular Dystrophy (LGMD) Natural History

Condition: Muscular Dystrophies, Limb-Girdle (GENETICALLY CONFIRMED)
Intervention:
Sponsors: Carolinas Healthcare System; Susan Sparks; Muscular Dystrophy Association
Recruiting - verified June 2013
A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)

Condition: Breast Cancer
Interventions: Drug: trastuzumab emtansine; Drug: trastuzumab
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; National Surgical Adjuvant Breast and Bowel Project (NSABP); German Breast Group
Recruiting - verified June 2013
Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects

Condition: Asthma
Interventions: Drug: FS Spiromax; Drug: Fluticasone propionate Spiromax; Drug: Advair Diskus
Sponsors: Teva Pharmaceutical Industries; Teva Branded Pharmaceutical Products, R&D Inc.
Recruiting - verified May 2013
Safety, Efficacy and Pharmacokinetics of ALD403

Condition: Migraine
Intervention: Biological: ALD403
Sponsors: Alder Biopharmaceuticals, Inc.; Alder Biopharmaceuticals, Inc.
Recruiting - verified May 2013
Study Comparing Clindamycin Phosphate and Benzoyl Peroxide Gel to Acanya® Gel and Both to a Vehicle Control in the Treatment of Acne Vulgaris

Condition: Acne Vulgaris
Interventions: Drug: Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%; Drug: Acanya® Gel, 1.2%/2.5%; Drug: Vehicle of test product
Sponsors: Taro Pharmaceuticals USA; Taro Pharmaceuticals USA
Recruiting - verified June 2013
A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer

Condition: Squamous Non Small Cell Lung Cancer
Interventions: Drug: Necitumumab; Drug: Paclitaxel; Drug: Carboplatin
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013
Evaluation of the VEGA Knee System® Range of Motion

Condition: Patients With Total Knee Arthroplasty Using the VEGA System®
Intervention:
Sponsors: Aesculap Implant Systems; Aesculap Implant Systems
Recruiting - verified June 2013
A Phase 2 Study to See if Simtuzumab (GS-6624) is Safe and Works in Idiopathic Pulmonary Fibrosis (IPF)

Condition: Idiopathic Pulmonary Fibrosis
Interventions: Drug: Simtuzumab (GS-6624); Drug: Placebo
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified June 2013
Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients

Condition: Type 2 Diabetes
Interventions: Drug: lixisenatide (AVE0010); Drug: insulin glulisine (HMR1964)
Sponsors: Sanofi; Sanofi
Recruiting - verified June 2013
Modified Barium Swallow in Measuring Swallowing Function After Surgery in Patients With Oropharyngeal Cancer

Condition: Oropharyngeal Cancer
Interventions: Procedure: diagnostic imaging; Other: questionnaire administration; Procedure: quality-of-life assessment
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Not yet recruiting - verified May 2013
The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF)

Conditions: Amnestic Mild Cognitive Impairment; Alzheimer's Disease
Interventions: Drug: Insulin (Humulin® R U-100); Drug: Placebo
Sponsors: Alzheimer's Disease Cooperative Study (ADCS); Alzheimer's Disease Cooperative Study (ADCS)
Not yet recruiting - verified June 2013
A Pharmacokinetics Study to Investigate the Effect of Ketoconazole on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma

Condition: Malignant Melanoma, Neoplasms
Interventions: Drug: vemurafenib; Drug: ketoconazole
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified June 2013
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

Condition: Dyslipidemia
Interventions: Device: AMG 145; Device: Placebo; Drug: Atorvastatin
Sponsors: Amgen; Amgen
Recruiting - verified June 2013
LDL-C Assessment w/ PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2

Condition: Hyperlipidemia
Interventions: Drug: AMG 145; Other: Ezetimibe; Other: Placebo (administered subcutaneously); Other: Placebo (administered orally); Drug: Statin therapy
Sponsors: Amgen; Amgen
Recruiting - verified June 2013
Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2

Condition: Hyperlipidemia
Interventions: Drug: AMG 145; Other: Placebo (administered subcutaneously); Drug: Ezetimibe; Other: Placebo (administered orally)
Sponsors: Amgen; Amgen
Recruiting - verified June 2013
Mechanistic Assessment of the Properties of Saxagliptin in Subjects Undergoing Coronary Artery Bypass Graft Surgery

Conditions: Type 2 Diabetes Mellitus; Cardiovascular Disease
Intervention: Drug: Saxagliptin
Sponsors: Duke University; Duke University
Recruiting - verified June 2013
Efficacy and Safety Study of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy

Condition: Glomerulonephritis, Membranous
Interventions: Drug: Belimumab 10 mg; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
Efficacy and Safety Study of Oral Solithromycin (CEM-101) Compared to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia

Condition: Community-acquired Bacterial Pneumonia
Interventions: Drug: Solithromycin; Drug: Moxifloxacin
Sponsors: Cempra Pharmaceuticals; Cempra Pharmaceuticals
Recruiting - verified June 2013
Long-term Open-Label Safety Study to Evaluate EN3409

Conditions: Low Back Pain; Osteoarthritis; Neuropathic Pain
Intervention: Drug: EN3409
Sponsors: Endo Pharmaceuticals; Endo Pharmaceuticals; BioDelivery Science International, Inc. (BDSI)
Recruiting - verified February 2013
Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Intravenous Therapy in Patients With Prosthetic Joint Infections

Condition: Prosthetic Joint Infections of Hip or Knee Joints
Interventions: Drug: CEM-102 plus Rifampin; Drug: IV vancomycin, nafcillin, oxacillin, ceftriaxone or cefazolin
Sponsors: Cempra Pharmaceuticals; Cempra Pharmaceuticals
Recruiting - verified June 2013
A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor

Condition: Rheumatoid Arthritis
Interventions: Drug: VX-509; Drug: VX-509 matching placebo
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated
Recruiting - verified May 2013
Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease

Condition: Diabetic Kidney Disease
Interventions: Drug: BMS-813160; Drug: Placebo matching with BMS-813160
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified June 2013
Registry for Integrative Medicine Interventions Effectiveness

Condition: All Conditions of Integrative Medicine Clinic Patients
Intervention:
Sponsors: Duke University; Duke University; The Bravewell Collaborative
Not yet recruiting - verified May 2013
An Open-Label Extension Study To Assess Long Term Safety And Effectiveness Of Dysport In Adults With Cervical Dystonia (CD)

Condition: Cervical Dystonia
Intervention: Drug: Dysport
Sponsors: Ipsen; Ipsen
Not yet recruiting - verified May 2013
3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy

Condition: Prostate Cancer
Interventions: Drug: Abiraterone acetate; Drug: Abiraterone acetate plus degarelix; Drug: Degarelix
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Janssen Pharmaceuticals; OHSU Knight Cancer Institute; Cancer Institute of New Jersey; NorthShore University HealthSystem Research Institute; Duke University; Feinberg School of Medicine, Northwestern University; Sidney Kimmel Comprehensive Cancer Center; University of North Carolina; Wayne State University
Recruiting - verified May 2013
Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia

Condition: Post Herpetic Neuralgia
Interventions: Drug: NXN-462; Drug: Placebo
Sponsors: NeurAxon Inc.; NeurAxon Inc.
Recruiting - verified June 2013
Efficacy and Safety Study of Z160 in Subjects With Postherpetic Neuralgia

Condition: Postherpetic Neuralgia
Interventions: Drug: Z160; Drug: Placebo
Sponsors: Zalicus; Zalicus
Recruiting - verified June 2013
Efficacy of Inhaled Albuterol Spiromax® in Subjects With Persistent Asthma With Steady State Pharmacokinetics

Condition: Asthma
Interventions: Drug: Albuterol Spiromax® 90 mcg/inhalation; Drug: Placebo Spiromax
Sponsors: Teva Pharmaceutical Industries; Teva Branded Pharmaceutical Products, R&D Inc.
Recruiting - verified May 2013
Safety and Pharmacokinetic Study of N6022 in Subjects With Cystic Fibrosis Homozygous for the F508del-CFTR Mutation

Condition: Cystic Fibrosis
Interventions: Drug: N6022; Drug: Normal saline
Sponsors: N30 Pharmaceuticals, Inc.; N30 Pharmaceuticals, Inc.
Recruiting - verified June 2013
Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis Patients

Condition: Cystic Fibrosis
Interventions: Drug: Vancomycin inhalation powder; Drug: Placebo inhalation powder
Sponsors: Savara Inc.; Savara Inc.; Synteract, Inc.
Recruiting - verified June 2013
Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT

Conditions: Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome (MDS)
Intervention: Drug: Treosulfan
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; National Marrow Donor Program; Resource for Clinical Investigation in Blood and Marrow Transplantation (RCI BMT); Pediatric Blood and Marrow Transplant Consortium; St. Baldrick's Foundation; medac GmbH
Not yet recruiting - verified May 2013
Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain

Condition: Advanced Idiopathic Parkinson's Disease
Interventions: Drug: Rotigotine; Drug: Placebo
Sponsors: UCB, Inc.; UCB BIOSCIENCES GmbH
Recruiting - verified May 2013
Attain Performa(TM) Quadripolar Lead Study

Condition: Heart Failure
Intervention: Device: Device: Attain Performa Pacing Lead (along with a standard CRT-D system)
Sponsors: Medtronic Cardiac Rhythm Disease Management; Medtronic Cardiac Rhythm Disease Management
Recruiting - verified May 2013
Study Comparing Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% to Epiduo® and Both to a Placebo Control in the Treatment of Acne Vulgaris

Condition: Acne Vulgaris
Interventions: Drug: Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%; Drug: Epiduo® Gel; Drug: Placebo
Sponsors: Taro Pharmaceuticals USA; Taro Pharmaceuticals USA
Recruiting - verified June 2013
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)

Condition: Alzheimer's Disease
Interventions: Drug: MK-8931; Drug: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2013
Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia

Conditions: Relapsed Acute Lymphoblastic Leukemia; Relapsed Acute Myelogenous Leukemia
Intervention: Drug: GNKG168
Sponsors: Therapeutic Advances in Childhood Leukemia Consortium; Therapeutic Advances in Childhood Leukemia Consortium
Recruiting - verified May 2013
S-ICD® System Post Approval Study

Conditions: Primary Prevention of Sudden Cardiac Arrest; Secondary Prevention of Sudden Cardiac Arrest
Intervention: Device: S-ICD System
Sponsors: Cameron Health, Inc.; Cameron Health, Inc.; Boston Scientific Corporation
Recruiting - verified May 2013
Evaluation of Purified Poloxamer 188 in Children in Crisis (EPIC)

Conditions: Vaso-occlusive Crisis; Sickle Cell Disease
Interventions: Drug: ANX-188; Drug: Saline
Sponsors: Mast Therapeutics, Inc.; Mast Therapeutics, Inc.
Recruiting - verified June 2013
An Extension (Rollover) Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol

Condition: Neoplasms
Intervention: Drug: vemurafenib
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified June 2013
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Condition: Alzheimer's Disease
Interventions: Drug: ELND005; Drug: Placebo
Sponsors: Elan Pharmaceuticals; Elan Pharma International Limited; Elan Pharmaceuticals
Recruiting - verified June 2013
Study Investigating a PEGylated Recombinant Factor VIII (BAX 855) for Hemophilia A (PROLONG-ATE Study)

Condition: Hemophilia A
Interventions: Biological: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method; Biological: PEGylated Recombinant Factor VIII; Biological: PEGylated Recombinant Factor VIII; Biological: PEGylated Recombinant Factor VIII
Sponsors: Baxter Healthcare Corporation; Baxter Healthcare Corporation
Recruiting - verified June 2013
Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission

Condition: Leukemia, Myeloid, Acute
Interventions: Drug: 300 mg Oral Azacitidine; Drug: Placebo
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified June 2013
Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers >12 cm2 to ≤ 36 cm2

Condition: Venous Leg Ulcers
Interventions: Biological: HP802-247; Biological: Vehicle
Sponsors: Healthpoint; Healthpoint
Recruiting - verified May 2013
Multidetector Computed Tomography (MDCT) Tailored Protocol

Condition: Patients Undergoing Contrast Enhanced Multidetector Computed Tomography of the Chest, Abdomen, Liver or Aorta for Any Diagnostic Cause
Intervention:
Sponsors: Bracco Diagnostics, Inc; Bracco Diagnostics, Inc
Recruiting - verified May 2013
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Linagliptin; Drug: Empagliflozin + Linagliptin; Drug: Empagliflozin + Linagliptin; Drug: Empagliflozin + Linagliptin; Drug: Empaglifozin placebo + Linagliptin placebo; Drug: Empagliflozin + Linagliptin
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified June 2013
Video Impact on Neulasta Education

Condition: Breast Cancer
Interventions: Other: Educational DVD 1; Other: Educational DVD 2
Sponsors: Amgen; Amgen
Recruiting - verified June 2013
Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma

Conditions: Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Recurrent Adult Brain Tumor
Interventions: Biological: bevacizumab; Radiation: intensity-modulated radiation therapy; Radiation: 3-dimensional conformal radiation therapy; Radiation: proton beam radiation therapy
Sponsors: Radiation Therapy Oncology Group; Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
Safety and Efficacy of Bioabsorbable Drug-Eluting Sinus Implant for Chronic Sinusitis

Condition: Chronic Sinusitis
Interventions: Drug: S8 sinus implant; Drug: continued nasal steroid spray
Sponsors: Intersect ENT; Intersect ENT
Recruiting - verified June 2013
Ipilimumab With or Without Talimogene Laherparepvec in Unresectable Melanoma

Condition: Melanoma
Interventions: Drug: Talimogene laherparepvec plus ipilimumab; Drug: Ipilimumab
Sponsors: Amgen; Amgen
Recruiting - verified June 2013
Dose-Confirming Study of Pulsed Inhaled Nitric Oxide in Subjects With WHO Group 3 Pulmonary Hypertension Associated With COPD

Conditions: Pulmonary Hypertension; Chronic Obstructive Pulmonary Disease
Interventions: Drug: Inhaled nitric oxide; Other: Placebo
Sponsors: INO Therapeutics; INO Therapeutics
Recruiting - verified May 2013
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese

Condition: Type 2 Diabetes in Obese Subjects
Interventions: Device: EndoBarrier; Procedure: Sham Procedure
Sponsors: GI Dynamics; GI Dynamics
Recruiting - verified May 2013
A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.

Condition: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Drug: QVA149; Drug: Long acting muscarinic antagonist (LAMA); Drug: Long acting B2 agonist (LABA); Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified June 2013
CO Mitochondrial Biogenesis

Conditions: Cardiac Disease; Mitochondrial Biogenesis; Carbon Monoxide
Intervention: Drug: 200ppm CO for one hour
Sponsors: Duke University; John J Freiberger
Not yet recruiting - verified May 2013
PK of Antistaphylococcal Antibiotics in Infants (NICHD-2012-02-Staph Trio)

Condition: Systemic Infection
Intervention: Drug: Antibiotic
Sponsors: Duke University; Phillip Brian Smith
Recruiting - verified June 2013
Maternal and Neurodevelopmental Outcomes of in Utero Antiepileptic Drug (AED) Exposure

Conditions: Epilepsy; Pregnancy
Intervention:
Sponsors: Emory University; Emory University; The EMMES Corporation
Recruiting - verified June 2013
A Controlled Study of Stem Cell Transplantation Medical Home Care Compared to Standard Hospital Care

Condition: Hematologic Malignancies
Intervention: Other: Home Care
Sponsors: Duke University; Duke University
Recruiting - verified May 2013
LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations

Conditions: Stage III Melanoma; Stage IV Melanoma; Unresectable Melanoma; BRAF Mutant Melanoma
Intervention: Drug: BRAF inhibitor dabrafenib and MEK inhibitor trametinib
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; GlaxoSmithKline
Recruiting - verified June 2013
Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease

Condition: Parkinson's Disease
Interventions: Drug: Rasagiline; Drug: Placebo
Sponsors: Teva Pharmaceutical Industries; Teva Branded Pharmaceutical Products, R&D Inc.
Recruiting - verified June 2013
Update and Biodistribution of [F-18]FMDHT pET/CT in Normal Healthy Volunteers and Patients With Metastatic Prostate Cancer - A First in Human Subject Study With [F-18] FMDHT

Condition: Prostate Cancer
Intervention: Drug: [F-18] fluorinated dihydrotestosterone (FDHT)
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University
Recruiting - verified May 2013
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Condition: Unresectable or Metastatic Melanoma
Interventions: Biological: BMS-936558; Drug: Dacarbazine; Drug: Carboplatin; Drug: Paclitaxel
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified May 2013
An Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (PCI-32765 Versus Chlorambucil)

Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Intervention: Drug: PCI-32765
Sponsors: Pharmacyclics; Pharmacyclics
Recruiting - verified June 2013
Study of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Squamous Cell Non-Small Cell Lung Cancer Who Have Received At Least Two Prior Systemic Regimens

Condition: Squamous Cell Non-small Cell Lung Cancer
Intervention: Drug: Nivolumab (BMS-936558)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified May 2013
A Study in Moderate to Severe Rheumatoid Arthritis Participants

Condition: Rheumatoid Arthritis
Interventions: Drug: Placebo; Drug: Baricitinib
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

Conditions: Diabetes Mellitus, Type 2; Hyperglycemia
Interventions: Drug: Empagliflozin low dose qd; Drug: Metformin 500 mg bid; Drug: Metformin 1000 mg bid; Drug: Empagliflozin high dose qd; Drug: Empagliflozin low dose bid; Drug: Metformin 500 mg bid; Drug: Empagliflozin high dose bid; Drug: Empagliflozin low dose bid; Drug: Metformin 1000 mg bid; Drug: Metformin 500 mg bid; Drug: Metformin 1000 mg bid; Drug: Empagliflozin high dose bid; Drug: Metformin 1000 mg bid; Drug: Empagliflozin high dose bid
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified June 2013
A Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 Versus Chlorambucil in Patients 65 Years or Older With Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (RESONATE™-2)

Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Interventions: Drug: PCI-32765; Drug: Chlorambucil
Sponsors: Pharmacyclics; Pharmacyclics
Recruiting - verified June 2013
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder

Condition: Binge Eating Disorder
Interventions: Drug: SPD489 (Lisdexamfetamine dimesylate); Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2013
A Multicenter, Phase II Study to Evaluate Velusetrag Effects on Gastric Emptying in Subjects With Diabetic or Idiopathic Gastroparesis

Condition: Gastroparesis
Interventions: Drug: velusetrag dose 1; Drug: velusetrag dose 2; Drug: velusetrag dose 3; Drug: placebo
Sponsors: Theravance, Inc.; Theravance, Inc.; Alfa Wassermann S.p.A.
Recruiting - verified June 2013
FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer

Condition: Colorectal Cancer Metastatic
Interventions: Drug: FOLFOX6m; Device: SIR-Spheres microspheres
Sponsors: Sirtex Medical; Sirtex Medical
Recruiting - verified June 2013
A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

Condition: Cardiovascular Disease, Diabetes Mellitus, Type 2
Interventions: Drug: aleglitazar; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified June 2013
The MURDOCK Study Community Registry and Biorepository Multiple Sclerosis Cohort

Condition: Multiple Sclerosis
Intervention:
Sponsors: Duke University; Duke University
Recruiting - verified May 2013
Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment

Conditions: Acne Vulgaris; Isotretinoin
Intervention:
Sponsors: Duke University; Duke University
Recruiting - verified June 2013
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis

Condition: Lupus Nephritis
Interventions: Biological: BMS-188667; Drug: Mycophenolate mofetil; Drug: Prednisone; Biological: Placebo matching with BMS-188667
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified June 2013
A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy

Condition: Atrial Fibrillation
Interventions: Drug: rivaroxaban; Drug: uninterrupted vitamin K antagonist (VKA)
Sponsors: Janssen Scientific Affairs, LLC; Janssen Scientific Affairs, LLC
Recruiting - verified June 2013
A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy

Condition: Diabetic Nephropathy
Interventions: Drug: PF-04634817; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
A Study of the Comparable Efficacy and Safety of Pulmozyme (Dornase Alfa) Delivered by the eFlow Rapid Nebulizer System in Patients With Cystic Fibrosis

Condition: Cystic Fibrosis
Interventions: Drug: dornase alfa [Pulmozyme]; Drug: dornase alfa [Pulmozyme]
Sponsors: Genentech; Genentech
Recruiting - verified May 2013
A Study in Moderate to Severe Rheumatoid Arthritis

Condition: Rheumatoid Arthritis
Interventions: Drug: Placebo; Drug: Adalimumab; Drug: Baricitinib
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013
Safety and Efficacy Study of GRT6005 in Patients With Osteoarthritis (OA) Knee Pain

Condition: Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee
Interventions: Drug: GRT6005 Low-Dose Range; Drug: GRT6005 High-Dose Range; Drug: Placebo; Drug: Oxycodone CR
Sponsors: Forest Laboratories; Forest Laboratories; Grünenthal GmbH
Recruiting - verified May 2013
Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)

Condition: Amyotrophic Lateral Sclerosis
Interventions: Drug: CK-2017357; Other: Placebo tablets
Sponsors: Cytokinetics; Cytokinetics
Recruiting - verified June 2013
VERtebral Fracture Treatment Comparisons in Osteoporotic Women

Condition: Postmenopausal Osteoporosis
Interventions: Drug: Teriparatide; Drug: Risedronate; Drug: Placebo; Drug: Calcium; Drug: Vitamin D
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013
Vitamin D3 in Pediatric SLE

Condition: Systemic Lupus Erythematosus
Intervention: Drug: Vitamin D3
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); Autoimmunity Centers of Excellence
Recruiting - verified June 2013
The MURDOCK Study Registry and Biorepository Horizon 1.5

Conditions: Chronic Disease; Healthy Volunteers
Intervention: Genetic: Biomarker studies
Sponsors: Duke University; Duke University
Recruiting - verified May 2013
To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)

Condition: Rheumatoid Arthritis
Interventions: Drug: sarilumab SAR153191 (REGN88); Other: placebo
Sponsors: Sanofi; Sanofi; Regeneron Pharmaceuticals
Recruiting - verified June 2013
Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Women

Conditions: Acquired Immunodeficiency Syndrome; HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir df; Drug: ritonavir + atazanavir + emtricitabine/tenofovir df
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified June 2013
Belimumab Assessment of Safety in SLE

Condition: Systemic Lupus Erythematosus
Interventions: Biological: Placebo plus standard therapy; Biological: Belimumab 10 mg/kg plus standard therapy; Other: Standard therapy
Sponsors: GlaxoSmithKline; Human Genome Sciences Inc., a GSK Company; GlaxoSmithKline
Recruiting - verified June 2013
Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer

Conditions: Breast Cancer; HER2-negative Breast Cancer
Interventions: Drug: Paclitaxel; Drug: Eribulin; Drug: Doxorubicin; Drug: Cyclophosphamide
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Surgical Adjuvant Breast and Bowel Project (NSABP); Eisai Inc.
Recruiting - verified June 2013
Study of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (Odyssey Alternative)

Condition: Hypercholesterolemia
Interventions: Drug: alirocumab (REGN727/ SAR236553); Drug: Active Comparator 1 (ezetimibe); Drug: Active Comparator 2 (atorvastatin); Other: Placebo 1 (placebo for ezetimibe atorvastatin); Other: Placebo 2 [alirocumab (REGN727/ SAR236553)]
Sponsors: Regeneron Pharmaceuticals; Regeneron Pharmaceuticals; Sanofi
Recruiting - verified May 2013
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline

Condition: Alzheimer's Disease
Intervention: Drug: florbetapir (18F)
Sponsors: Avid Radiopharmaceuticals; Avid Radiopharmaceuticals; Eli Lilly and Company
Recruiting - verified June 2013
The Medication Experience Study

Conditions: Hypertension; Elevated Cholesterol; Diabetes; Depression
Intervention: Other: Internet Survey
Sponsors: Wake Forest University; Wake Forest University
Recruiting - verified May 2013
Almased Multi-Center Diabetes Intervention Trial

Conditions: Type 2 Diabetes; Obesity
Interventions: Dietary Supplement: Almased Meal Replacement Powder; Behavioral: Group-Based Lifestyle Intervention
Sponsors: Wake Forest University; Wake Forest University; University of Freiburg; University of Campinas, Brazil; London Metropolitan University; University of Mysore, India
Recruiting - verified June 2013
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)

Condition: Atrial Fibrillation
Intervention: Other: Patients with Atrial Fibrillation
Sponsors: Janssen Scientific Affairs, LLC; Janssen Scientific Affairs, LLC; Duke Clinical Research Institute
Recruiting - verified May 2013
The Efficacy and Safety and Tolerability of Laquinimod in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

Condition: Multiple Sclerosis (MS)
Interventions: Drug: Laquinimod 0.6 mg; Drug: Matching Placebo; Drug: Laquinimod 1.2 mg
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Recruiting - verified May 2013
The CARRA Registry

Conditions: Juvenile Idiopathic Arthritis; Systemic Lupus Erythematosus; Mixed Connective Tissue Disease; Juvenile Ankylosing Spondylitis; Juvenile Dermatomyositis; Localized Scleroderma; Systemic Sclerosis; Vasculitis; Sarcoid; Fibromyalgia, Primary; Auto-inflammatory Disease; Idiopathic Uveitis Idiopathic
Intervention:
Sponsors: Duke University; Duke University; National Institutes of Health (NIH); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified August 2012
Reverse Shoulder Arthroplasty With or Without Concomitant Latissimus and Teres Major Transfer for Shoulder Pseudoparalysis With Teres Minor Dysfunction

Condition: Osteoarthritis of the Shoulder
Interventions: Procedure: Transfer group; Procedure: Control group
Sponsors: OrthoCarolina Research Institute, Inc.; OrthoCarolina Research Institute, Inc.
Recruiting - verified October 2012
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Tiotropium; Drug: Placebo matching Olodaterol; Drug: Tiotropium; Drug: Olodaterol
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified June 2013
First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

Condition: Gastric Cancer
Interventions: Drug: Rilotumumab; Other: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified June 2013
Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia

Condition: High Risk Acute Myeloid Leukemia
Interventions: Drug: CPX-351; Drug: 7+3 (cytarabine and daunorubicin)
Sponsors: Celator Pharmaceuticals; Celator Pharmaceuticals; The Leukemia and Lymphoma Society
Recruiting - verified May 2013
A Study of Ixekizumab in Participants With Active Psoriatic Arthritis

Condition: Psoriasis, Arthritic
Interventions: Drug: ixekizumab; Drug: Placebo; Drug: Adalimumab
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013
A Randomized, Double Blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Ulcerative Colitis

Condition: Ulcerative Colitis
Interventions: Biological: AMG 181; Other: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified June 2013
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects

Condition: Moderate to Severe Plaque Psoriasis
Interventions: Drug: 210 mg brodalumab; Drug: 140 mg brodalumab; Drug: ustekinumab; Drug: placebo
Sponsors: Amgen; Amgen
Recruiting - verified June 2013
Phase 2 Study of TD-9855 to Treat Fibromyalgia

Condition: Fibromyalgia
Interventions: Drug: TD-9855 Group 1; Drug: TD-9855 Group 2; Drug: Placebo
Sponsors: Theravance, Inc.; Theravance, Inc.
Recruiting - verified May 2013
A Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus Who Have Not Previously Received Anti-Hyperglycemic Therapy

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: aleglitazar; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified June 2013
Safety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation

Condition: Clostridium Difficile-Associated Diarrhea (CDAD)
Interventions: Drug: fidaxomicin; Drug: placebo
Sponsors: Optimer Pharmaceuticals; Optimer Pharmaceuticals
Recruiting - verified June 2013
Low Dose Naltrexone-buprenorphine Transfer to Vivitrol Injection in Opioid Dependence

Condition: Opiate Dependence
Interventions: Drug: very low dose naltrexone; Drug: extended release naltrexone; Drug: buprenorphine/naloxone
Sponsors: Duke University; Paolo Mannelli; Alkermes
Recruiting - verified May 2013
Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis

Conditions: Psoriasis; Psoriatic Arthritis
Interventions: Drug: Apremilast 30 mg; Drug: Etanercept 50 mg; Drug: Placebo tablet; Drug: Placebo injection (saline)
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified June 2013
Surgical Treatment of Aortic Stenosis With a Next Generation, Rapid Deployment Surgical Aortic Valve

Conditions: Aortic Valve Stenosis; Aortic Valve Stenosis With Insufficiency; Regurgitation, Aortic Valve; Aortic Valve Incompetence
Intervention: Device: EDWARDS INTUITY valve
Sponsors: Edwards Lifesciences; Edwards Lifesciences
Recruiting - verified April 2013
Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma

Condition: Multiple Myeloma
Intervention: Drug: PRLX 93936
Sponsors: Prolexys Pharmaceuticals; Prolexys Pharmaceuticals
Recruiting - verified May 2013
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Condition: Malignant Melanoma
Interventions: Drug: vemurafenib; Drug: Placebo; Drug: GDC-0973
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified June 2013
Adult Attention Deficit Hyperactivity Disorder

Condition: Adult Attention Deficit Hyperactivity Disorder
Interventions: Drug: SEP-225289; Drug: SEP-225289; Drug: Placebo
Sponsors: Sunovion; Sunovion
Recruiting - verified June 2013
Efficacy and Safety Study With Diltiazem Hydrochloride Cream to Treat Anal Fissures

Condition: Chronic Anal Fissures
Interventions: Drug: VEN 307; Drug: Placebo
Sponsors: Ventrus Biosciences, Inc; Ventrus Biosciences, Inc
Recruiting - verified June 2013
Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Postherpetic Neuralgia (PHN)

Conditions: Postherpetic Neuralgia; Pain
Interventions: Drug: V116517 50-mg tablets; Drug: V116517 30-mg tablets; Drug: Pregabalin capsules; Drug: Placebo
Sponsors: Purdue Pharma LP; Purdue Pharma LP
Recruiting - verified June 2013
Finding Predictors of Side Effects to Chemoradiation Treatment in Elderly Patients With Head and Neck Cancer

Condition: Head and Neck Cancer
Intervention: Other: Collect Blood and Survey Instruments
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center
Recruiting - verified June 2013
FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer

Condition: Pancreatic Cancer
Intervention: Drug: FOLFIRINOX
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center
Recruiting - verified June 2013
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects

Condition: Moderate to Severe Plaque Psoriasis
Interventions: Drug: 210 mg brodalumab; Drug: 140 mg brodalumab; Drug: ustekinumab; Drug: placebo
Sponsors: Amgen; Amgen
Recruiting - verified June 2013
A Study of Evacetrapib in High-Risk Vascular Disease

Condition: Cardiovascular Diseases
Interventions: Drug: Evacetrapib; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company; The Cleveland Clinic
Recruiting - verified June 2013
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease

Condition: Diabetic Kidney Disease
Interventions: Drug: baricitinib; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Incyte Corporation
Recruiting - verified June 2013
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB in Patients With COPD Who Have Moderate to Severe Airflow Limitation

Condition: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Drug: QVA149; Drug: Long acting b2-agonist; Drug: QVA149; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified June 2013
A First-in-Human Phase 1 and Expanded Cohort Study of EPZ-5676 in Advanced Hematologic Malignancies, Including Acute Leukemia With Rearrangement of the MLL Gene

Conditions: Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Myelodysplastic Syndrome; Myeloproliferative Disorders; Chronic Myeloid Leukemia
Intervention: Drug: EPZ-5676
Sponsors: Epizyme, Inc.; Epizyme, Inc.; Celgene Corporation
Recruiting - verified June 2013
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life

Condition: Measles, Mumps and Rubella Diseases
Interventions: Biological: GSK Bilogicals measles, mumps and rubella vaccine live (GSK 209762).; Biological: Merck & Co., Inc.'s M-M-R®II, combined measles-mumps-rubella virus vaccine live.; Biological: Varivax® (Merck & Co., Inc.); Biological: Havrix®; Biological: Prevnar 13® (Pfizer Inc.)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib

Condition: Non-Small Cell Lung Cancer
Intervention: Drug: LDK378
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified June 2013
LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer

Condition: Non-Small Cell Lung Cancer
Intervention: Drug: LDK378
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified June 2013
A Dose Range Finding Study of JNJ-38518168 in Patients With Active Rheumatoid Arthritis in Spite of Treatment With Methotrexate

Condition: Rheumatoid Arthritis
Interventions: Drug: Placebo; Drug: JNJ-38518168 (3 mg); Drug: JNJ-38518168 (10 mg); Drug: JNJ-38518168 (30 mg)
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified June 2013
The COX-2 Gene and the Immune System

Conditions: Cyclooxygenase-2; Lymphocyte; Eicosanoid; Prostaglandin
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Environmental Health Sciences (NIEHS)
Recruiting - verified April 2013
MAyflOwer RoAD Study: A Study of RO4602522 in Patients With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy

Condition: Alzheimer Disease
Interventions: Drug: RO4602522; Drug: RO4601522; Drug: placebo; Drug: donepezil; Drug: rivastigmine; Drug: galantamine; Drug: memantine
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified June 2013
Clinical Outcome Study for Dysferlinopathy

Conditions: Dysferlinopathy; LGMD2B; Miyoshi Myopathy
Intervention:
Sponsors: Newcastle-upon-Tyne Hospitals NHS Trust; Newcastle-upon-Tyne Hospitals NHS Trust; Jain Foundation (Grant sponsor)
Recruiting - verified October 2012
Efficacy Study to Evaluate EN3409 in Opioid-Experienced Subjects

Condition: Low Back Pain
Intervention: Drug: EN3409
Sponsors: Endo Pharmaceuticals; Endo Pharmaceuticals; BDSI - BioDelivery Science International, Inc.
Recruiting - verified October 2012
Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Condition: Atrial Fibrillation
Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939); Drug: Vitamin K antagonist (VKA)
Sponsors: Bayer; Bayer; Janssen Research & Development, LLC
Recruiting - verified May 2013
Safety and Efficacy Study of Hydromorphone HCl by Intrathecal Administration Using a Programmable Implantable Pump

Condition: Management of Chronic Pain
Interventions: Drug: Hydromorphone Hydrochloride; Drug: Hydromorphone Hydrochloride
Sponsors: CNS Therapeutics; CNS Therapeutics; Pacific-Link Consulting LLC
Recruiting - verified June 2013
Safety and Efficacy Study of ELND005 as an Adjunctive Maintenance Treatment in Bipolar I Disorder

Condition: Bipolar 1 Disorder
Interventions: Drug: ELND005; Drug: Lamotrigine; Drug: Valproic acid; Drug: Placebo
Sponsors: Elan Pharmaceuticals; Elan Pharma International Limited; Elan Pharmaceuticals
Recruiting - verified June 2013
Study of BMS-936558 Compared to Docetaxel in Previously Treated Advanced or Metastatic Non-squamous NSCLC

Condition: Non-Squamous Cell Non-small Cell Lung Cancer
Interventions: Biological: BMS-936558; Drug: Docetaxel
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified May 2013
Renal Stent Placement for the Treatment of Renal Artery Stenosis in Patients With Resistant Hypertension

Conditions: Renal Artery Stenosis; Hypertension, Renovascular
Intervention: Device: iCAST™ Rx Stent System
Sponsors: Atrium Medical Corporation; Atrium Medical Corporation
Recruiting - verified May 2013
Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus

Condition: Diabetes Melliuts, Type 2
Interventions: Other: Placebo; Drug: 25 mg PF-05231023; Drug: 50 mg PF-05231023; Drug: 100 mg PF-05231023; Drug: 150 mg PF-05231023
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis With Significant Comorbidities in Very High Risk Subjects Who Need Aortic Valve Replacement

Condition: Severe Aortic Stenosis
Intervention: Device: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
Sponsors: Medtronic Cardiovascular; Medtronic Cardiovascular
Recruiting - verified May 2013
GS-6624 in the Treatment of Cirrhosis Due to NASH

Condition: Non-Alcoholic Steatohepatitis (NASH)
Interventions: Biological: GS-6624 700mg; Biological: GS-6624 200mg; Biological: Placebo
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013
GS-6624 in the Treatment of Liver Fibrosis in Subjects With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)

Condition: Non-Alcoholic Steatohepatitis (NASH)
Interventions: Biological: GS-6624 75 mg; Biological: GS-6624 125 mg; Biological: Placebo
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013
GS-6624 in the Prevention of Progression of Liver Fibrosis in Subjects With With Primary Sclerosing Cholangitis (PSC)

Condition: Primary Sclerosing Cholangitis (PSC)
Interventions: Biological: GS-6624; Biological: Placebo
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013
Early Supplementation of Enteral Microlipid With and Without Fish Oil in Premature Infants With Enterostomies

Conditions: Prematurity; Intestine Perforation; Necrotizing Enterocolitis (NEC); Short Bowel Syndrome (SBS)
Interventions: Dietary Supplement: Microlipid and fish oil; Dietary Supplement: Microlipid
Sponsors: Wake Forest University; Wake Forest University
Recruiting - verified May 2013
Neratinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

Condition: Breast Neoplasms
Intervention: Drug: neratinib
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified June 2013
A Phase 2 Diagnostic Imaging Study With 99mTc-MIP-1404 in Men With High-Risk Prostate Cancer Scheduled for Radical Prostatectomy (RP) and Extended Pelvic Lymph Node Dissection (EPLND) Compared to Histopathology

Condition: Prostate Cancer
Intervention: Drug: Drug: 99mTc-MIP-1404
Sponsors: Molecular Insight Pharmaceuticals, Inc.; Molecular Insight Pharmaceuticals, Inc.
Recruiting - verified May 2013
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Conditions: Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer
Interventions: Drug: pegylated liposomal doxorubicin (PLD); Drug: VTX-2337; Drug: Placebo
Sponsors: VentiRx Pharmaceuticals Inc.; VentiRx Pharmaceuticals Inc.; Gynecologic Oncology Group
Recruiting - verified June 2013
Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis

Condition: Arthritis, Rheumatoid
Interventions: Drug: BI 695500; Drug: BI 695500; Drug: rituximab; Drug: rituximab; Drug: rituximab
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified June 2013
Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 1

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: tiotropium bromide; Drug: Placebo
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified June 2013
Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: Paclitaxel; Drug: Bevacizumab [Avastin]; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified June 2013
Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 2

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: tiotropium bromide; Drug: Placebo
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified June 2013
Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With SAR236553 (REGN727) (ODYSSEY Outcomes)

Condition: Acute Coronary Syndrome
Interventions: Drug: SAR236553 (REGN727); Other: placebo
Sponsors: Sanofi; Sanofi; Regeneron Pharmaceuticals
Recruiting - verified June 2013
Observational Study of Optical Coherence Tomography (OCT) in Patients Undergoing Fractional Flow Reserve (FFR) and Percutaneous Coronary Intervention

Condition: Single or Multi Vessel Disease
Intervention:
Sponsors: St. Jude Medical; St. Jude Medical
Recruiting - verified May 2013
Efficacy and Safety of SAR339658 in Patients With Moderate to Severe Ulcerative Colitis

Condition: Ulcerative Colitis
Interventions: Drug: SAR339658; Other: Placebo
Sponsors: Sanofi; Sanofi
Recruiting - verified June 2013
A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis

Conditions: Deep Vein Thrombosis; Venous Thrombosis
Interventions: Drug: edoxaban tosylate; Drug: enoxaparin/unfractionated heparin; Drug: warfarin
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.
Recruiting - verified June 2013
Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers

Condition: Venous Leg Ulcers
Interventions: Biological: HP-802-247; Biological: Vehicle
Sponsors: Healthpoint; Healthpoint; Smith & Nephew, Inc.
Recruiting - verified June 2013
Open Label Extension in Adults With Binge Eating Disorder (BED)

Condition: Binge Eating Disorder
Intervention: Drug: Lisdexamfetamine dimesylate
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified June 2013
Efficacy and Safety of Ularitide for the Treatment of Acute Decompensated Heart Failure

Condition: Acute Decompensated Heart Failure
Interventions: Drug: Ularitide; Drug: Placebo
Sponsors: Cardiorentis; Cardiorentis; Quintiles
Recruiting - verified June 2013
Phase I/II Study of Capecitabine Plus Aflibercept to Treat Metastatic Colorectal Cancer

Condition: Metastatic Colorectal Cancer
Intervention: Drug: Capecitabine and aflibercept
Sponsors: Duke University; Fatima Rangwala; Sanofi
Recruiting - verified May 2013
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)

Condition: Fibrosing Colonopathy in Patients With Cystic Fibrosis
Interventions: Biological: CREON; Biological: ZENPEP; Biological: ULTRESA; Biological: PANCREAZE; Biological: other non-sponsor pancreatic enzyme replacement therapy; Other: No pancreatic enzyme replacement therapy
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott); Aptalis Pharma; Cystic Fibrosis Foundation; Janssen Research & Development, LLC
Recruiting - verified May 2013
The Performance of the APPY1 Test in the Evaluation of Possible Acute Appendicitis

Condition: Acute Appendicitis
Intervention:
Sponsors: Venaxis, Inc.; Venaxis, Inc.
Recruiting - verified May 2013
A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: empagliflozin (low dose qd); Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Empagliflozin (high dose qd); Drug: empagliflozin (high dose bid); Drug: Placebo; Drug: empagliflozin (low dose bid)
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified June 2013
Afatinib Expanded Access Program

Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: afatinib
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Available - verified June 2013
Efficacy and Safety Study of RPC1063 in Ulcerative Colitis

Condition: Ulcerative Colitis
Interventions: Drug: RPC1063; Drug: placebo
Sponsors: Receptos, Inc.; Receptos, Inc.
Recruiting - verified June 2013
A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3)

Condition: Psoriasis
Interventions: Drug: 80 mg ixekizumab; Drug: 50 mg etanercept; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013
Efficacy and Safety of SAR236553 (REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Combo II)

Condition: Hypercholesterolemia
Interventions: Drug: SAR236553 (REGN727); Drug: matching placebo SAR236553 (REGN727); Drug: Ezetimibe; Drug: matching placebo for Ezetimibe
Sponsors: Sanofi; Sanofi; Regeneron Pharmaceuticals
Recruiting - verified June 2013
Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF

Condition: Cystic Fibrosis
Interventions: Drug: Aztreonam for Inhalation Solution (AZLI); Drug: Placebo
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified July 2012
Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules in Treating Symptomatic Non-Erosive Gastroesophageal Reflux Disease in Adolescents

Condition: Gastroesophageal Reflux Disease
Intervention: Drug: Dexlansoprazole
Sponsors: Takeda; Takeda
Recruiting - verified June 2013
A Phase 2 Study Evaluating Ganetespib in Women With Metastatic HER2+ or Triple Negative Breast Cancer

Conditions: Breast Cancer; HER-2 Positive Breast Cancer; Triple Negative Breast Cancer
Intervention: Drug: ganetespib
Sponsors: Synta Pharmaceuticals Corp.; Synta Pharmaceuticals Corp.
Recruiting - verified May 2013
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Conditions: Inflammation; Rheumatoid Arthritis
Interventions: Drug: NNC0109-0012; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified June 2013
Rheumatoid Arthritis Extension Trial For Subjects Who Have Participated In Other PF-05280586 Trials (REFLECTIONS B328-04)

Condition: Rheumatoid Arthritis
Interventions: Biological: Rituximab-Pfizer (PF-05280586) x 3 courses; Biological: Rituximab-EU+ Rituximab-Pfizer x 2 Courses; Biological: Rituximab-US + Rituximab-Pfizer x 2 Courses
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
Sacroiliac Joint Fusion With iFuse Implant System (SIFI)

Conditions: Degenerative Sacroiliitis; Sacroiliac Joint Disruption
Intervention:
Sponsors: SI-BONE, Inc.; SI-BONE, Inc.
Recruiting - verified June 2013
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Condition: Relapsing-remitting Multiple Sclerosis (RRMS)
Interventions: Drug: fingolimod; Drug: copaxone
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified June 2013
Effectiveness of Beclomethasone Dipropionate Nasal Aerosol for Perennial Allergic Rhinitis

Condition: Perennial Allergic Rhinitis (PAR)
Intervention: Drug: Beclomethasone Dipropionate (BDP) Nasal Aerosol
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries; United BioSource Corporation
Recruiting - verified May 2013
A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Conditions: Small Lymphocytic Lymphoma; Chronic Lymphocytic Leukemia
Interventions: Drug: ABT-199; Drug: Rituximab
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott); Genentech
Recruiting - verified May 2013
A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer

Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Custirsen + Docetaxel; Drug: Docetaxel
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Recruiting - verified June 2013
Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis Patients

Condition: Relapsing Multiple Sclerosis
Interventions: Drug: RPC1063; Drug: placebo; Drug: RPC1063
Sponsors: Receptos, Inc.; Receptos, Inc.
Recruiting - verified June 2013
Osteonecrosis of the Jaw (ONJ) Case Registry

Condition: Osteonecrosis of the Jaw (ONJ)
Intervention:
Sponsors: Amgen; Amgen
Recruiting - verified June 2013
Safety and Efficacy of the Journey II BCS Total Knee System

Condition: Osteoarthritis, Knee
Intervention: Device: TKA with Journey II BCS Total Knee System
Sponsors: Smith & Nephew, Inc.; Smith & Nephew, Inc.
Recruiting - verified June 2013
Naive T-Cell Depleted DLI Following Allo Stem Cell Transplant

Condition: Hematological Malignancies
Intervention: Biological: Naive T Cell Depleted Donor Lymphocyte Infusion
Sponsors: Duke University; Mitchell Horwitz
Recruiting - verified May 2013
Clinical Outcomes Assessment of the MitraClip Therapy Percutaneous Therapy for High Surgical Risk Patients

Conditions: Mitral Regurgitation; Mitral Valve Regurgitation
Intervention: Device: MitraClip System
Sponsors: Evalve; Evalve; Abbott Vascular
Recruiting - verified May 2013
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)

Condition: Behavioral Variant Frontotemporal Dementia (bvFTD)
Interventions: Drug: TRx0237; Drug: Placebo
Sponsors: TauRx Therapeutics Ltd; TauRx Therapeutics Ltd
Recruiting - verified May 2013
A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

Conditions: Type 2 Diabetes; Chronic Kidney Disease
Interventions: Drug: Dulaglutide; Drug: Insulin glargine; Drug: Insulin lispro
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age

Condition: Measles, Mumps and Rubella Diseases
Interventions: Biological: Priorix®; Biological: Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine (also known as M-M-R Vax Pro™); Biological: Kinrix®; Biological: Varivax®
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
A Study Of PF-00547659 In Patients With Moderate To Severe Ulcerative Colitis

Condition: Ulcerative Colitis
Interventions: Drug: PF-00547659 SC Injection; Drug: PF-00547659 SC Injection; Drug: PF-00547659 SC Injection; Drug: PF-00547659 SC Injection; Drug: PF-00547659 SC Injection
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis

Condition: Idiopathic Pulmonary Fibrosis
Interventions: Biological: Tralokinumab; Biological: Tralokinumab; Other: Placebo
Sponsors: MedImmune LLC; MedImmune LLC
Recruiting - verified May 2013
Efficacy and Safety of SAR236553 (REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY High FH)

Condition: Hypercholesterolaemia
Interventions: Drug: SAR236553 (REGN727); Drug: placebo
Sponsors: Sanofi; Sanofi; Regeneron Pharmaceuticals
Recruiting - verified June 2013
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease

Condition: Management of Anemia in Chronic Kidney Disease Patients Not on Dialysis.
Intervention: Biological: Darbepoetin alfa
Sponsors: Amgen; Amgen
Recruiting - verified June 2013
Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3

Condition: Hepatitis C Virus (HCV)
Interventions: Biological: Pegylated interferon lambda (pegIFNλ); Biological: Pegylated interferon lambda (pegIFNλ); Biological: Pegylated interferon alfa-2a (pegIFNα-2a); Drug: Ribavirin; Drug: Ribavirin; Drug: Daclatasvir; Drug: Placebo matching Daclatasvir
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified June 2013
Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: GTx-758 125 mg; Drug: GTx-758 250 mg; Drug: GTx-758 500 mg
Sponsors: GTx; GTx
Recruiting - verified June 2013
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients

Condition: Cytomegalovirus Infections
Intervention: Drug: Maribavir
Sponsors: ViroPharma; ViroPharma
Recruiting - verified June 2013
Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A

Condition: Herpes Zoster (HZ)
Interventions: Biological: Herpes Zoster vaccine GSK1437173A; Biological: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified June 2013
Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Conditions: Type 2 Diabetes; Cardiovascular Disease
Interventions: Drug: TAK-875; Drug: TAK-875 Placebo
Sponsors: Takeda; Takeda
Recruiting - verified June 2013
Lung Volume Reduction Coil for Treatment in Patients With Emphysema (RENEW) Study

Condition: Emphysema
Intervention: Device: PneumRx RePneu Lung Volume Reduction Coil (RePneu LVRC) System
Sponsors: PneumRx, Inc.; PneumRx, Inc.
Recruiting - verified December 2012
A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND)

Condition: Arthritis, Rheumatoid
Interventions: Drug: Placebo; Drug: Placebo; Drug: Sirukumab; Drug: Sirukumab; Drug: Sirukumab
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified June 2013
A Study of Necitumumab Monotherapy and the QT/QTc Interval in Patient With Advanced Solid Tumors

Condition: Solid Tumors
Intervention: Biological: necitumumab
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified April 2013
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Conditions: Prostate Cancer; Castration Resistant Prostate Cancer; Pain; Prostatic Neoplasms
Interventions: Drug: cabozantinib; Drug: prednisone
Sponsors: Exelixis; Exelixis
Recruiting - verified June 2013
A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND)

Condition: Arthritis, Rheumatoid
Interventions: Drug: Placebo; Drug: Placebo; Drug: Sirukumab; Drug: Sirukumab; Drug: Sirukumab
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified June 2013
Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors

Conditions: Childhood Central Nervous System Choriocarcinoma; Childhood Central Nervous System Embryonal Tumor; Childhood Central Nervous System Germ Cell Tumor; Childhood Central Nervous System Germinoma; Childhood Central Nervous System Mixed Germ Cell Tumor; Childhood Central Nervous System Teratoma; Childhood Central Nervous System Yolk Sac Tumor; Childhood Pineal Parenchymal Tumor
Interventions: Procedure: therapeutic conventional surgery; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy; Drug: carboplatin; Drug: etoposide; Drug: ifosfamide
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
Efficacy and Safety of TBS-2 Testosterone Gel in Women With Acquired Female Orgasmic Disorder

Condition: Female Orgasmic Disorder
Interventions: Drug: Placebo; Drug: Low dose TBS-2; Drug: Medium dose TBS-2; Drug: High dose TBS-2
Sponsors: Trimel Biopharma SRL; Trimel Biopharma SRL
Recruiting - verified June 2013
A Study to Evaluate the Safety and Efficacy of AC607 for the Treatment of Kidney Injury in Cardiac Surgery Subjects

Condition: Acute Kidney Injury
Interventions: Biological: AC607; Biological: Vehicle Only
Sponsors: AlloCure Inc.; AlloCure Inc.
Recruiting - verified June 2013
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Interventions: Drug: Ibrutinib; Drug: Bendamustine hydrochloride; Drug: Rituximab; Drug: Placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharmacyclics
Recruiting - verified June 2013
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Condition: Breast Cancer
Interventions: Drug: BKM120 Matching placebo; Drug: Fulvestrant; Drug: BKM120
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Condition: Melanoma
Interventions: Drug: Dabrafenib; Drug: Vemurafenib; Drug: Trametinib
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified June 2013
A Noninferiority Study of Alglucosidase Alfa Manufactured at the 160 L and 4000 L Scales in Patients With Infantile-Onset Pompe Disease Who Have Never Been Treated

Conditions: Pompe Disease (Infantile-Onset); Glycogen Storage Disease Type II (GSD II); Glycogenosis 2; Acid Maltase Deficiency
Interventions: Biological: alglucosidase alfa; Biological: alglucosidase alfa
Sponsors: Genzyme; Genzyme
Recruiting - verified May 2013
A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2)

Condition: Psoriasis
Interventions: Drug: 80 mg ixekizumab Dosing Regimen; Drug: 50 mg etanercept; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013
Bovine Lactoferrin in Reducing Taste Disturbances in Patients With Colorectal Cancer Receiving Oxaliplatin-Based Chemotherapy

Conditions: Colorectal Cancer; Dysgeusia; Oral Complications of Chemotherapy
Interventions: Other: questionnaire administration; Procedure: quality-of-life assessment; Other: laboratory biomarker analysis; Biological: bovine lactoferrin
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified May 2013
Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer

Condition: Advanced HER2-positive Breast Cancer or Gastric Cancer
Interventions: Drug: LJM716; Drug: Trastuzumab
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified June 2013
Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial

Condition: Solid Tumors
Interventions: Drug: Iniparib (SAR240550/BSI-201); Drug: Carboplatin; Drug: Doxorubicin HCL liposome injection; Drug: Gemcitabine; Drug: Irinotecan; Drug: Paclitaxel; Drug: Topotecan
Sponsors: Sanofi; Sanofi
Recruiting - verified June 2013
Neoadjuvant Dose Dense Gemcitabine and Cisplatin (DD GC) In Patients With Muscle-Invasive Bladder Cancer

Condition: Bladder Cancer
Intervention: Drug: Gemcitabine and Cisplatin (DD GC)
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; University of North Carolina, Chapel Hill; New York University
Recruiting - verified June 2013
A Clinical Trial for the Surgical Treatment of Elderly Distal Radius Fractures

Condition: Distal Radius Fracture
Interventions: Procedure: Open Reduction and Internal Fixation; Procedure: External Fixation; Procedure: Percutaneous Pinning; Procedure: Closed Reduction and casting
Sponsors: University of Michigan; University of Michigan; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); National Institute on Aging (NIA)
Recruiting - verified May 2013
Preventative Trial of DFMO in Patients With High Risk Neuroblastoma in Remission

Condition: Neuroblastoma in Remission
Intervention: Drug: DFMO
Sponsors: Van Andel Research Institute; Giselle Sholler; Cancer Prevention Pharmaceuticals, Inc.; University of Arizona; University of Hawaii; University of Vermont
Recruiting - verified May 2013
Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement (SURTAVI).

Condition: Severe Aortic Stenosis
Interventions: Device: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI); Procedure: Surgical Aortic Valve Replacement (SAVR)
Sponsors: Medtronic Cardiovascular; Medtronic Cardiovascular
Recruiting - verified June 2013
Adenovirus Vaccine Pregnancy Registry

Condition: Adenovirus
Intervention:
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries; Department of Defense
Recruiting - verified June 2013
Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)

Conditions: Advanced Renal Cell Carcinoma; Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma
Interventions: Drug: Standard Treatment; Biological: AGS-003
Sponsors: Argos Therapeutics; Argos Therapeutics
Recruiting - verified June 2013
Efficacy and Safety Dose Titration Study of Botulinum Toxin Type A to Treat Spasticity in the Leg and Arm

Condition: Spasticity of the Upper and Lower Limb Due to Cerebral Causes
Intervention: Drug: IncobotulinumtoxinA
Sponsors: Merz Pharmaceuticals GmbH; Merz Pharmaceuticals GmbH
Recruiting - verified June 2013
Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Condition: Venous Thromboembolism (VTE)
Interventions: Drug: Betrixaban; Drug: Enoxaparin
Sponsors: Portola Pharmaceuticals; Portola Pharmaceuticals
Recruiting - verified June 2013
A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours

Conditions: Carcinoid Tumor of the Small Bowel; Neuroendocrine Tumour
Interventions: Drug: Octreotide; Drug: Octreotide; Drug: 177Lu-DOTA0-Tyr3-Octreotate
Sponsors: Advanced Accelerator Applications; Advanced Accelerator Applications; Pierrel Research Europe GmbH
Recruiting - verified June 2013
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: cabazitaxel, prednisone, custirsen sodium; Drug: cabazitaxel, prednisone
Sponsors: OncoGenex Technologies; OncoGenex Technologies; Teva Pharmaceutical Industries
Recruiting - verified May 2013
Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing-Remitting Multiple Sclerosis

Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Biological: MEDI-551; Drug: Placebo
Sponsors: MedImmune LLC; MedImmune LLC; PPD
Recruiting - verified June 2013
Study To Evaluate Cardiac Assessments Following Different Treatments Of Smoking Cessation Medications In Subjects With And Without Psychiatric Disorders.

Condition: Smoking Cessation
Interventions: Drug: placebo; Drug: varenicline tartrate; Drug: bupropion hydrochloride; Drug: Nicotine Replacement Therapy Patch
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort

Condition: Huntington's Disease
Intervention:
Sponsors: CHDI Foundation, Inc.; CHDI Foundation, Inc.
Recruiting - verified May 2013
Pharmacokinetics and Safety of Ertapenem in the Postpartum Period

Condition: Endometritis
Intervention: Drug: Ertapenem
Sponsors: Duke University; Daniel Benjamin
Recruiting - verified June 2013
Registrational Study With AMG 785 to Treat Postmenopausal Osteoporosis

Condition: Postmenopausal Osteoporosis
Interventions: Drug: AMG 785; Drug: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified June 2013
Pilot Study of Catheter Ablation for Ventricular Tachycardia in Patients With an Implantable Cardioverter Defibrillator

Condition: Ventricular Tachycardia
Interventions: Drug: amiodarone; Drug: sotalol; Device: Biosense Webster's NAVI-STAR Thermo-Cool
Sponsors: Duke University; Duke University; Duke Clinical Research Institute
Recruiting - verified June 2013
A Research Study of an Investigational Drug ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride) in Patients With Moderate to Severe Chronic Low Back Pain

Conditions: Chronic Pain; Low Back Pain; Analgesia
Interventions: Drug: ALO-02; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis

Condition: Arthritis, Rheumatoid
Interventions: Drug: ASP015K; Drug: Placebo
Sponsors: Astellas Pharma Inc; Astellas Pharma Global Development, Inc.
Recruiting - verified June 2013
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Conditions: Relapsed Multiple Myeloma; Refractory Multiple Myeloma
Interventions: Drug: MLN9708 + Lenalidomide + Dexamethasone; Drug: Placebo + Lenalidomide + Dexamethasone
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified June 2013
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

Condition: Alzheimer's Disease
Interventions: Drug: LY2886721; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013
A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Who Have Had an Inadequate Response to Methotrexate

Condition: Arthritis, Rheumatoid
Interventions: Drug: ASP015K; Drug: Placebo
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc
Recruiting - verified June 2013
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)

Condition: Major Depressive Disorder, Recurrent
Interventions: Drug: MK-6096; Drug: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2013
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma

Conditions: Neurofibromatosis Type 1; Recurrent Childhood Pilocytic Astrocytoma; Recurrent Childhood Visual Pathway Glioma
Intervention: Drug: lenalidomide
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified June 2013
Baminercept in Sjögren's Syndrome

Condition: Sjögren's Syndrome
Interventions: Biological: Baminercept; Other: Placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified June 2013
Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d) (Protocol JNJ-27018966IBS3001)

Condition: Irritable Bowel Syndrome
Interventions: Drug: JNJ-27018966; Drug: Placebo
Sponsors: Furiex Pharmaceuticals, Inc; Furiex Pharmaceuticals, Inc
Recruiting - verified June 2013
Pediatric Arthritis Study of Certolizumab Pegol

Condition: Juvenile Idiopathic Arthritis (JIA)
Intervention: Drug: Certolizumab Pegol (CZP)
Sponsors: UCB, Inc.; UCB BIOSCIENCES GmbH
Recruiting - verified June 2013
Comparison of TAK-875 to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes

Condition: Glycemic Control
Interventions: Drug: TAK-875; Drug: Sitagliptin; Drug: Placebo
Sponsors: Takeda; Takeda Global Research & Development Centre (Europe) Ltd.
Recruiting - verified June 2013
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder

Condition: Attention-deficit/Hyperactivity Disorder
Interventions: Drug: Lisdexamfetamine dimesylate; Drug: Methylphenidate Hydrochloride; Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2013
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)

Conditions: Chronic Inflammatory Demyelinating Polyneuropathy; Polyradiculoneuropathy
Interventions: Biological: IgPro20; Biological: Placebo
Sponsors: CSL Behring; CSL Behring; Parexel
Recruiting - verified May 2013
Prospective Collection of Female and Male Specimens for PANTHER® System Testing

Conditions: Chlamydia Infections; Gonorrhea
Intervention: Device: APTIMA Assays; PANTHER System
Sponsors: Gen-Probe, Incorporated; Gen-Probe, Incorporated
Recruiting - verified June 2013
Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) On A Background Of Tiotropium Bromide

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: PH-797804; Drug: PH-797804; Drug: PH-797804; Drug: PH-797804; Drug: PH-797804; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study

Condition: Irritable Bowel Syndrome With Diarrhea
Interventions: Drug: rifaximin; Drug: placebo
Sponsors: Salix Pharmaceuticals; Salix Pharmaceuticals
Recruiting - verified January 2013
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy

Condition: Colorectal Neoplasms
Intervention: Drug: Regorafenib (BAY73-4506)
Sponsors: Bayer; Bayer
Available - verified June 2013
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Condition: Crohn's Disease
Interventions: Drug: GSK1605786A; Drug: GSK1605786A
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified June 2013
Effect of Rotigotine on Motor Symptoms in Patients With Advanced Parkinson's Disease (PD) With Motor Fluctuations and Symptoms of Gastrointestinal Dysfunction

Condition: Advanced Parkinson's Disease
Interventions: Drug: Rotigotine; Drug: Placebo
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified June 2013
A Study to Evaluate the Efficacy and Safety of a Single Application of QUTENZA Compared to That of Placebo in Reducing Pain Intensity in Subjects With Painful Diabetic Peripheral Neuropathy (PDPN)

Conditions: Diabetic Peripheral Neuropathy; Pain
Interventions: Drug: QUTENZA; Drug: Placebo
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc
Recruiting - verified June 2013
Efficacy and Safety of NVC-422 in the Treatment of Adenoviral Conjunctivitis

Condition: Adenoviral Conjunctivitis
Interventions: Drug: NVC-422 Ophthalmic Solution, 0.33%; Drug: Vehicle Ophthalmic Solution
Sponsors: NovaBay Pharmaceuticals, Inc.; NovaBay Pharmaceuticals, Inc.
Recruiting - verified June 2013
Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia

Condition: Hypertriglyceridemia
Interventions: Drug: ISIS apoC-III Rx; Drug: ISIS apoC-III Rx; Drug: ISIS apoC-III Rx; Drug: Placebo; Drug: Placebo; Drug: Placebo
Sponsors: Isis Pharmaceuticals; Isis Pharmaceuticals
Recruiting - verified June 2013
A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia

Condition: Schizophrenia
Interventions: Drug: PP3M 175 mg eq.; Drug: PP3M 263 mg eq.; Drug: PP3M 350 mg eq.; Drug: PP3M 525 mg eq.; Drug: Placebo (20% Intralipid emulsion)
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified June 2013
Safety and Efficacy Continued Access Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in Very High Risk Subjects and High Risk Subjects Who Need Aortic Valve Replacement

Condition: Severe Aortic Stenosis
Intervention: Device: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
Sponsors: Medtronic Cardiovascular; Medtronic Cardiovascular
Recruiting - verified May 2013
Remote Ischemic Preconditioning Mechanism Study

Condition: Pain
Intervention: Device: Remote Ischemic Preconditioning, Capsaicin, UV-B
Sponsors: Wake Forest University Baptist Medical Center; Wake Forest University Baptist Medical Center
Recruiting - verified May 2013
A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)

Condition: Rheumatoid Arthritis
Interventions: Biological: PF-05280586; Biological: MabThera; Biological: Rituxan
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
A Study to Determine the Effect of Tiotropium + Olodaterol Fixed Dose Combination on Exercise Endurance Time During Constant Work Load Cycle Test in COPD

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: tiotropium + olodaterol (high dose); Drug: tiotropium+olodaterol; Drug: placebo to tiotropium+olodaterol
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified June 2013
Blood Vessel Study

Conditions: Cardiovascular; P450s; Flow-Mediated Dilation; Brachial Artery Ultrasound; Endothelial Cell Function
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Environmental Health Sciences (NIEHS)
Recruiting - verified October 2012
The Safety, Tolerability, PK and PD of GSK2586881 in Patients With Acute Lung Injury

Condition: Lung Injury, Acute
Interventions: Drug: Dose 1 GSK2586881; Drug: Dose 2 GSK2586881; Drug: Dose 3 GSK2586881; Drug: Dose 4 GSK2586881; Drug: Placebo (saline)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases

Condition: Prostatic Neoplasms
Intervention: Drug: Radium-223 dichloride (BAY88-8223)
Sponsors: Bayer; Bayer
Available - verified June 2013
Symptom-Adapted Physical Activity Intervention in Minimizing Physical Function Decline in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy

Conditions: Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Recurrent Adult Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia
Interventions: Procedure: quality-of-life assessment; Other: counseling intervention; Behavioral: exercise intervention; Other: educational intervention; Procedure: standard follow-up care
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified May 2013
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis

Condition: Rheumatoid Arthritis
Interventions: Biological: Certolizumab Pegol + Methotrexate (MTX); Biological: Placebo + Methotrexate (MTX)
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified June 2013
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis

Condition: Rheumatoid Arthritis
Interventions: Biological: Certolizumab Pegol + Methotrexate (MTX); Biological: Placebo + Methotrexate (MTX)
Sponsors: UCB, Inc.; UCB Pharma SA
Recruiting - verified June 2013
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia

Condition: Schizophrenia
Interventions: Drug: PP3M 175 mg eq.; Drug: PP3M 263 mg eq.; Drug: PP3M 350 mg eq.; Drug: PP3M 525 mg eq.; Drug: Placebo (20% Intralipid); Drug: PP1M 50 mg eq.; Drug: PP1M 75 mg eq.; Drug: PP1M 100 mg eq.; Drug: PP1M 150 mg eq.
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified June 2013
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Conditions: Prostate Cancer; Castration Resistant Prostate Cancer; Pain; Prostatic Neoplasms
Interventions: Drug: cabozantinib; Drug: mitoxantrone; Drug: prednisone
Sponsors: Exelixis; Exelixis
Recruiting - verified June 2013
Seprafilm in Open Abdomens: a Study of Wound and Adhesion Characteristics in Trauma Damage Control Patients

Conditions: Open Wound of Other and Unspecified Parts of Abdomen; Trauma
Intervention: Biological: Seprafilm
Sponsors: Ohio State University; Stanislaw Stawicki
Recruiting - verified June 2013
Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in Men Who Have Sex With Men and in At-Risk Women

Condition: HIV Infection
Interventions: Drug: Maraviroc; Drug: Emtricitabine; Drug: Tenofovir disoproxil fumarate; Other: Maraviroc placebo; Other: Emtricitabine placebo; Other: Tenofovir disoproxil fumarate placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); HIV Prevention Trials Network
Recruiting - verified June 2013
Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children

Condition: HIV Infections
Intervention: Drug: Etravirine (ETR)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified June 2013
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer

Conditions: Childhood Hepatocellular Carcinoma; Papillary Thyroid Cancer; Previously Treated Childhood Rhabdomyosarcoma; Recurrent Childhood Liver Cancer; Recurrent Childhood Rhabdomyosarcoma; Recurrent Thyroid Cancer; Recurrent Wilms Tumor and Other Childhood Kidney Tumors
Interventions: Drug: sorafenib tosylate; Other: pharmacological study; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified June 2013
Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SUN13837 Injection in Adult Subjects With Acute Spinal Cord Injury (ASCI)

Condition: Acute Spinal Cord Injury
Interventions: Drug: SUN13837 injection; Drug: Placebo
Sponsors: Asubio Pharmaceuticals, Inc.; Asubio Pharmaceuticals, Inc.
Recruiting - verified June 2013
Minimally Invasive Groin Dissection for Melanoma

Condition: Melanoma
Intervention: Procedure: Minimally invasive inguinal lymph node dissection
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified May 2013
Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma

Condition: Mantle-Cell Lymphoma
Intervention: Drug: Rituximab, Bortezomib,Y90 ibritumomab tiuxetan
Sponsors: Duke University; Duke University; Spectrum Pharmaceuticals, Inc
Recruiting - verified June 2013
A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer

Condition: Non-Small Cell Lung Cancer
Interventions: Drug: onartuzumab; Drug: Placebo; Drug: paclitaxel; Drug: cisplatin/carboplatin
Sponsors: Genentech; Genentech
Recruiting - verified May 2013
A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer

Condition: Non-Small Cell Lung Cancer
Interventions: Drug: RO5490258; Drug: bevacizumab [Avastin]; Drug: pemetrexed; Drug: Placebo; Drug: cisplatin/carboplatin; Drug: paclitaxel
Sponsors: Genentech; Genentech
Recruiting - verified May 2013
Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections

Condition: Complicated Skin and Soft Tissue Infection
Interventions: Drug: Ceftaroline fosamil; Drug: Vancomycin; Drug: Aztreonam
Sponsors: AstraZeneca; AstraZeneca; Cerexa, Inc.
Recruiting - verified June 2013
Safety and Efficacy of NNC 0155-0000-0004 in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A

Conditions: Congenital Bleeding Disorder; Haemophilia A
Intervention: Drug: turoctocog alfa
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified June 2013
The BEACON Study (Breast Cancer Outcomes With NKTR-102)

Conditions: Locally Recurrent Breast Cancer; Metastatic Breast Cancer
Interventions: Drug: NKTR-102; Drug: Treatment of Physician's Choice (TPC)
Sponsors: Nektar Therapeutics; Nektar Therapeutics
Recruiting - verified June 2013
AMR-001 Versus Placebo Post ST Segment Elevation Myocardial Infarction

Condition: ST Segment Elevation Myocardial Infarction
Interventions: Biological: AMR-001; Other: placebo
Sponsors: Amorcyte, Inc.; Amorcyte, Inc.
Recruiting - verified February 2013
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

Condition: High-risk Smoldering Multiple Myeloma
Interventions: Drug: Siltuximab; Drug: Placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified June 2013
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam

Condition: Epilepsy
Intervention: Drug: Lacosamide
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified May 2013
Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection

Conditions: HIV Infections; Hepatitis C
Interventions: Drug: Pegylated-Interferon Alfa 2b (PEG-IFN); Drug: Ribavirin (RBV); Drug: Boceprevir (BOC)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified June 2013
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: TAK-875; Drug: TAK-875; Drug: Glimepiride
Sponsors: Takeda; Takeda
Recruiting - verified June 2013
A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids

Condition: Asthma
Interventions: Drug: Placebo; Drug: Flovent Diskus; Drug: Fluticasone propionate DPI Dose 1; Drug: Fluticasone propionate DPI Dose 2; Drug: Fluticasone propionate DPI Dose 3; Drug: Fluticasone propionate DPI Dose 4
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries; PPD
Recruiting - verified May 2013
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma

Conditions: Glioblastoma; Small Cell Glioblastoma; Giant Cell Glioblastoma; Gliosarcoma; Glioblastoma With Oligodendroglial Component
Interventions: Drug: Rindopepimut (CDX-110) with GM-CSF; Drug: Temozolomide; Drug: KLH
Sponsors: Celldex Therapeutics; Celldex Therapeutics
Recruiting - verified June 2013
NBRST: Prospective Neo-adjuvant REGISTRY Trial

Condition: Breast Cancer
Interventions: Device: MammaPrint; Device: BluePrint; Device: TargetPrint; Device: TheraPrint
Sponsors: Agendia; Agendia
Recruiting - verified June 2013
Veliparib With Radiation Therapy in Patients With Inflammatory or Loco-regionally Recurrent Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Veliparib; Radiation: Standard radiation treatment
Sponsors: University of Michigan Cancer Center; University of Michigan Cancer Center
Recruiting - verified June 2013
IIT CTI Bendamustine, Rituximab, Pixantrone in Relapsed/Refractory B Cell Non-Hodgkin's Lymphoma

Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: Bendamustine + Rituximab + Pixantrone
Sponsors: Duke University; Anne Beaven; Cell Therapeutics
Recruiting - verified June 2013
Study of Heart Failure Hospitalizations After Aquapheresis Therapy Compared to Intravenous (IV) Diuretic Treatment

Conditions: Heart Failure; Cardiac Failure; Acute Decompensated Heart Failure (ADHF)
Interventions: Device: Isolated veno-venous ultrafiltration (AQ); Drug: IV Loop Diuretics (LD)
Sponsors: Gambro Renal Products, Inc.; Gambro Renal Products, Inc.; Gambro UF Solutions, Inc.
Recruiting - verified May 2013
HCV-TARGET- Hepatitis C Therapeutic Registry and Research Network

Condition: Hepatitis C
Intervention:
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; University of Florida
Recruiting - verified June 2013
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Condition: Colorectal Cancer
Interventions: Drug: GS-6624; Drug: FOLFIRI; Drug: GS-6624; Drug: FOLFIRI; Drug: GS-6624; Drug: FOLFIRI; Drug: Placebo; Drug: FOLFIRI
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013
A Multiple Dose Study Of PD-0360324 In Patients With Active Cutaneous Lupus Erythematosus

Condition: Cutaneous Lupus Erythematosus
Interventions: Drug: PD-0360324; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
Efficacy of LCQ908 on Cardiovascular Risk

Conditions: Coronary Artery Disease; Hypertriglyceridemia
Interventions: Drug: LCQ908; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013
Safety Study of Aztreonam Lysine for Inhalation (AZLI) in the Treatment of Early Bronchiolitis Obliterans Syndrome (BOS)

Condition: Complication of Transplanted Lung
Interventions: Drug: Aztreonam Lysine for Inhalation (AZLI); Procedure: Status Post Lung Transplant
Sponsors: Duke University; Duke University; Gilead Sciences
Recruiting - verified June 2013
Efficacy of Fluocinonide Cream 0.1% (Vanos(R)) in Reducing Itch in Subjects With Atopic Dermatitis

Condition: Atopic Dermatitis
Intervention: Drug: Fluocinonide cream
Sponsors: Wake Forest University; Wake Forest University; Medicis Pharmaceutical Corporation
Recruiting - verified May 2013
Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder

Condition: Acute Depressive Episode
Interventions: Drug: Ramelteon SL; Drug: Ramelteon SL; Drug: Ramelteon SL; Drug: Placebo
Sponsors: Takeda; Takeda
Recruiting - verified June 2013
Efficacy and Safety of Ramelteon Sublingual as Adjunctive Therapy for Maintenance Treatment of Bipolar I Disorder in Adult Patients

Condition: Bipolar Disorder
Interventions: Drug: Ramelteon SL; Drug: Ramelteon SL; Drug: Ramelteon SL; Drug: Placebo
Sponsors: Takeda; Takeda
Recruiting - verified June 2013
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke

Condition: Post-stroke Spasticity of the Lower Limb.
Interventions: Drug: IncobotulinumtoxinA (400 Units); Drug: Placebo Comparator
Sponsors: Merz Pharmaceuticals GmbH; Merz Pharmaceuticals GmbH
Recruiting - verified June 2013
GLORIA-AF Registry Program - Second and Third Phases

Conditions: Stroke; Atrial Fibrillation
Intervention:
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified June 2013
A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease

Condition: Crohn's Disease
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
Evaluating the Effectiveness of the Quadrivalent Human Papillomavirus (HPV) Vaccine at Preventing Anal HPV Infection in HIV-Infected Men and Women

Condition: HIV Infections
Interventions: Biological: Quadrivalent HPV Vaccine; Biological: Placebo Vaccine for Male Participants Only; Biological: Placebo Vaccine for Female Participants Only
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified June 2013
A Study Of Oral CP-690550 As A Maintenance Therapy For Ulcerative Colitis

Condition: Ulcerative Colitis
Interventions: Drug: Placebo; Drug: CP690,550; Drug: CP690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis

Condition: Ulcerative Colitis
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis

Condition: Ulcerative Colitis
Interventions: Drug: tofacitinib; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis

Condition: Ulcerative Colitis
Interventions: Drug: tofacitinib; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
Study Of Dacomitinib In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO

Condition: Non Small Cell Lung Cancer (NSCLC)
Interventions: Drug: Dacomitinib Plus Blinded Doxycycline or Placebo; Drug: Dacomitinib Plus Probiotic Plus Topical Alclometasone cream; Drug: Dacomitinib
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
Effect Of Pregabalin Treatment In Patients With Diabetic Nerve Pain Who Currently Use A Non-Steroid Anti-Inflammatory Drug (NSAID) For Another Pain

Condition: Painful Diabetic Peripheral Neuropathy
Interventions: Drug: pregabalin; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures

Condition: Epilepsy, Partial Seizures
Intervention: Drug: Pregabalin
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders

Condition: Smoking Cessation
Interventions: Drug: Placebo; Drug: varenicline tartrate; Drug: bupropion hydrochloride; Drug: Nicotine Replacement Therapy Patch
Sponsors: Pfizer; Pfizer; GlaxoSmithKline
Recruiting - verified May 2013
Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device (LVAD) and Medical Management

Condition: Heart Failure
Interventions: Device: HM II (HeartMate II LVAD); Drug: OMM (Optimal Medical Management)
Sponsors: Thoratec Corporation; Thoratec Corporation
Recruiting - verified May 2013
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)

Conditions: Pulmonary Arterial Hypertension; Pulmonary Hypertension
Interventions: Drug: Nitric Oxide; Other: Placebo; Drug: Nitric Oxide
Sponsors: INO Therapeutics; INO Therapeutics
Recruiting - verified May 2013
Prospective Randomized Evaluation of a Two and Three Piece Total Ankle Replacement

Condition: Ankle Osteoarthritis
Intervention: Procedure: Total Ankle Replacement Surgery
Sponsors: Duke University; Duke University
Recruiting - verified May 2013
Study of the AeriSeal System for HyPerInflation Reduction in Emphysema (ASPIRE)

Condition: Pulmonary Emphysema
Interventions: Device: Treatment plus Optimal Medical Therapy; Other: Optimal Medical Therapy
Sponsors: Aeris Therapeutics; Aeris Therapeutics
Recruiting - verified June 2013
Pharmacokinetics (PK) of Liquid Hydroxyurea in Pediatric Patients With Sickle Cell Anemia

Condition: Sickle Cell Anemia
Intervention: Drug: Hydroxyurea
Sponsors: Children's Mercy Hospital Kansas City; Children's Mercy Hospital Kansas City; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified May 2013
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cancer
Interventions: Drug: AMG 386; Drug: Paclitaxel; Drug: AMG 386 Placebo; Drug: Carboplatin
Sponsors: Amgen; Amgen
Recruiting - verified June 2013
Open Label Study of Long Term Evaluation Against LDL-C Trial

Condition: Hypercholesterolemia
Interventions: Drug: AMG 145 and standard of care; Other: Standard of care
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
A Multi-Center, Randomized, Controlled Evaluation of the Safety and Efficacy of the KXL System With VibeX (Riboflavin Ophthalmic Solution) for Corneal Collagen Cross-Linking in Eyes With Keratoconus or Corneal Ectasia After Refractive Surgery

Conditions: Keratoconus; Corneal Ectasia
Interventions: Device: KXL System (15 mW/cm2); Device: KXL System (30 mW/cm2); Device: KXL System (45 mW/cm2); Drug: riboflavin ophthalmic solution
Sponsors: ACOS; ACOS
Recruiting - verified June 2013
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

Condition: Major Depressive Disorder
Interventions: Drug: SPD489 (Lisdexamfetamine dimesylate ); Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified June 2013
Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor BAY80-6946 With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer

Condition: Neoplasms
Interventions: Drug: Gemcitabine; Drug: BAY80-6946; Drug: Cisplatin; Drug: NaCl; Drug: BAY80-6964 fixed dose
Sponsors: Bayer; Bayer
Recruiting - verified June 2013
Radiation Therapy in Treating Patients With Prostate Cancer

Conditions: Prostate Cancer; Psychosocial Effects of Cancer and Its Treatment; Radiation Toxicity; Sexual Dysfunction
Intervention: Radiation: hypofractionated radiation therapy
Sponsors: Radiation Therapy Oncology Group; Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
Safety and Efficacy of OsmoPrep® Tablets Versus HalfLytely® and Bisacodyl Tablet Bowel Prep Kit for Colon Cleansing

Condition: Colon Cleansing
Interventions: Drug: Polyethylene glycol; Drug: Oral sodium phosphate solution
Sponsors: Salix Pharmaceuticals; Salix Pharmaceuticals
Recruiting - verified July 2012
Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) for Uncontrolled Moderate - Severe Low Back Pain

Condition: Low Back Pain
Interventions: Drug: Oxycodone/Naloxone controlled-release; Drug: Oxycodone HCl controlled-release; Drug: Placebo
Sponsors: Purdue Pharma LP; Purdue Pharma LP
Recruiting - verified June 2013
Vitamin D for Enhancing the Immune System in Cystic Fibrosis (DISC Study)

Conditions: Cystic Fibrosis; Respiratory Tract Infections
Intervention: Dietary Supplement: Cholecalciferol
Sponsors: Emory University; Emory University; Cystic Fibrosis Foundation
Recruiting - verified June 2013
Intracardiac CrYoablation for AtrioVentricular Nodal Reentrant Tachycardia

Conditions: AtrioVentricular Nodal Reentrant Tachycardia; Supraventricular Tachycardia; Heart Disease
Intervention: Device: Freezor Xtra Cryoablation Catheter
Sponsors: Medtronic Atrial Fibrillation Solutions; Medtronic Atrial Fibrillation Solutions
Recruiting - verified January 2013
Patient Controlled Tissue Expansion for Breast Reconstruction

Condition: Breast Cancer
Interventions: Device: AeroForm Tissue Expansion; Procedure: Saline Tissue Expansion
Sponsors: AirXpanders, Inc.; AirXpanders, Inc.
Recruiting - verified June 2013
A 12-week Study to Compare the Efficacy and Safety of Albuterol Spiromax® Versus a Placebo in People 12 Years and Older With Persistent Asthma

Condition: Asthma
Interventions: Drug: Placebo; Drug: Albuterol Spiromax®
Sponsors: Teva Pharmaceutical Industries; Teva Branded Pharmaceutical Products, R&D Inc.
Recruiting - verified May 2013
A Study of RG1662 in Individuals With Down Syndrome

Condition: Down Syndrome
Interventions: Drug: RG1662; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified June 2013
Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: GSK2110183; Drug: Bortezomib; Drug: Dexamethasone
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified February 2013
A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4

Conditions: Tumors; Medical Oncology; Neoplasms
Interventions: Drug: AGS-22M6E; Drug: ASG-22CE
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc; Agensys, Inc.; Seattle Genetics, Inc.
Recruiting - verified June 2013
Evaluating the Safety and Effectiveness of Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Individuals With Latent Tuberculosis Infection

Conditions: Tuberculosis; HIV Infections
Interventions: Drug: Rifapentine (RPT); Drug: Isoniazid (INH); Dietary Supplement: Pyridoxine (Vitamin B6)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2013
An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Intervention:
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)

Conditions: Alzheimer Disease; Mild Cognitive Impairment; Neurodegenerative Diseases
Intervention: Drug: Florbetapir F 18
Sponsors: Avid Radiopharmaceuticals; Avid Radiopharmaceuticals
Recruiting - verified June 2013
Safety, Tolerability, and Efficacy of Cariprazine for Patients With Bipolar Depression

Condition: Depression, Bipolar
Interventions: Drug: Placebo; Drug: Cariprazine; Drug: Cariprazine; Drug: Cariprazine
Sponsors: Forest Laboratories; Forest Laboratories; Gedeon Richter Ltd.
Recruiting - verified May 2013
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Conditions: Cardiovascular Disease; Diabetes Mellitus, Type 2
Interventions: Drug: Dulaglutide; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013
Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma

Conditions: Colorectal Carcinoma; CRC
Interventions: Biological: JX-594; Drug: Irinotecan
Sponsors: Jennerex Biotherapeutics; Jennerex Biotherapeutics; Transgene
Recruiting - verified January 2012
The Safety And Efficacy Of Maintenance Therapy With CP-690,550

Condition: Crohn's Disease
Interventions: Drug: Placebo; Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Condition: Crohn's Disease
Interventions: Drug: Placebo; Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
A Study of the Efficacy and Safety of Pregabalin as Add-On Therapy for Partial Onset Seizures in Children Ages 4-16 Years

Condition: Epilepsy, Partial Seizures
Interventions: Drug: Pregabalin add-on therapy; Drug: Pregabalin add-on therapy; Drug: Pregabalin add-on therapy
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)

Conditions: Cachexia; Non-Small Cell Lung Cancer
Interventions: Drug: Anamorelin HCl; Drug: Placebo
Sponsors: Helsinn Therapeutics (U.S.), Inc; Helsinn Therapeutics (U.S.), Inc
Recruiting - verified June 2013
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)

Conditions: Cachexia; Non-Small Cell Lung Cancer
Interventions: Drug: Anamorelin HCl; Drug: Placebo
Sponsors: Helsinn Therapeutics (U.S.), Inc; Helsinn Therapeutics (U.S.), Inc
Recruiting - verified June 2013
MRD Testing Before and After Hematopoietic Cell Transplantation Transplantation for Pediatric Acute Myeloid Leukemia

Condition: Acute Myeloid Leukemia
Intervention:
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; Resource for Clinical Investigations in Blood and Marrow Transplantation (RCI-BMT); Pediatric Blood and Marrow Transplant Consortium; St. Baldrick's Foundation; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified June 2013
Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer

Condition: Non-Small-Cell Lung Carcinoma
Interventions: Biological: TG4010; Drug: placebo
Sponsors: Transgene; Transgene
Recruiting - verified June 2013
Efficacy and Satisfaction Comparing Two Braces in the Treatment of Developmental Dysplasia of the Hip (DDH) in Infants

Conditions: Hip Dislocation, Congenital; Congenital Deformity of Hip Joint
Interventions: Other: Pavlik Brace; Other: Plastizote Brace
Sponsors: OrthoCarolina Research Institute, Inc.; OrthoCarolina Research Institute, Inc.
Recruiting - verified January 2012
Racial Disparity in Barrett's Esophagus

Conditions: Barrett's Esophagus; Gastroesophageal Reflux Disease (GERD); Intestinal Metaplasia
Intervention:
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; National Cancer Institute (NCI)
Recruiting - verified June 2013
Is the Neosquamous Epithelium "Normal" Following Endoscopic Ablation of Dysplastic Barrett's Esophagus?

Conditions: Barrett's Esophagus; Intestinal Metaplasia; Gastroesophageal Reflux Disease (GERD)
Intervention:
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; American Society for Gastrointestinal Endoscopy
Recruiting - verified June 2013
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD

Condition: Major Depressive Disorder
Interventions: Drug: desvenlafaxine succinate sustained release; Drug: fluoxetine; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD

Condition: Major Depressive Disorder
Intervention: Drug: DVS SR
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Synchronized Transcranial Magnetic Stimulation (sTMS) in Major Depressive Disorder

Condition: Major Depressive Disorder
Interventions: Device: NEST-1 (NeoSync EEG Synchronized TMS); Device: SHAM
Sponsors: NeoSync, Inc.; NeoSync, Inc.
Recruiting - verified June 2013
Proteomic Assessment of Preterm Birth

Condition: Preterm Birth
Intervention:
Sponsors: Sera Prognostics, Inc.; Sera Prognostics, Inc.
Recruiting - verified May 2013
A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Conditions: Crohn's Disease; Colitis; IBD; Inflammatory Bowel Disease
Interventions: Drug: Placebo; Drug: Ustekinumab; Drug: Ustekinumab; Drug: Ustekinumab; Drug: Ustekinumab
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified June 2013
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Conditions: Crohn's Disease; Inflammatory Bowel Disease; IBD; Colitis
Interventions: Drug: Group 3: ustekinumab approximately 6 mg/kg; Drug: Group 1: Placebo; Drug: Group 2 ustekinumab 130 mg
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified June 2013
Effect of Growth Hormone on Early Brain Development in Girls With Turner Syndrome

Condition: Turner Syndrome
Intervention: Drug: somatotropin
Sponsors: University of North Carolina, Chapel Hill; Marsha Davenport, MD; Pfizer
Recruiting - verified May 2013
Remote Ischemic PreConditioning Effect on Postsurgical Pain

Condition: Pain
Interventions: Device: Thigh Tourniquet (VBM Single Use Tourniquet Cuff Items 20-34-722SLZ-1); Device: Sham RIPC
Sponsors: Wake Forest University Baptist Medical Center; Wake Forest University Baptist Medical Center
Recruiting - verified May 2013
National Marrow Donor Program Long-Term Donor Follow-Up

Condition: Hematologic Neoplasms
Intervention:
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; National Marrow Donor Program
Recruiting - verified May 2013
Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer

Conditions: Pain; Advanced Cancer
Interventions: Drug: Sativex®; Drug: Placebo (GA-0034)
Sponsors: GW Pharmaceuticals Ltd.; GW Pharmaceuticals Ltd.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified August 2011
Phase I Biomarker Study (BMS-936558)

Condition: Renal Cell Carcinoma
Interventions: Drug: BMS-936558 (Anti-PD-1); Drug: BMS-936558 (Anti-PD-1); Drug: BMS-936558 (Anti-PD-1)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Ono Pharma USA Inc
Recruiting - verified May 2013
A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.

Condition: Healthy
Interventions: Biological: rLP2086; Other: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
A Study of Avastin (Bevacizumab) in Combination With Standard of Care Treatment in Patients With Lung Cancer

Condition: Non-Small Cell Lung Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: Standard of care treatment
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified June 2013
Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy

Conditions: Brain and Central Nervous System Tumors; Nausea and Vomiting; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Procedure: Real Acupressure Band; Procedure: Placebo Acupressure Band
Sponsors: University of South Florida; University of South Florida; National Cancer Institute (NCI)
Recruiting - verified May 2012
Patients Treated for SCID (1968-2010)

Conditions: SCID; ADA-SCID; XSCID; Leaky SCID; Omenn Syndrome; Reticular Dysgenesis
Intervention:
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); Office of Rare Diseases (ORD)
Recruiting - verified May 2013
Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With Ccr5 Tropic HIV 1

Condition: HIV-1
Interventions: Drug: Maraviroc; Drug: Emtricitabine/tenofovir
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Recruiting - verified June 2013
A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma

Condition: Advanced Liposarcoma or Leiomyosarcoma
Interventions: Drug: Trabectedin; Drug: Dacarbazine
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharma Mar, S.A.U.
Recruiting - verified June 2013
A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease

Condition: Multicentric Castleman's Disease
Intervention: Drug: Siltuximab
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2013
A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD.

Condition: Coronary Artery Disease
Intervention: Drug: Flurpiridaz F18
Sponsors: Lantheus Medical Imaging; Lantheus Medical Imaging
Recruiting - verified February 2013
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Fluticasone Furoate/Vilanterol; Drug: Vilanterol; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer

Conditions: Transitional Cell Carcinoma of Bladder; Urethra Cancer; Ureter Cancer; Malignant Tumor of Renal Pelvis
Interventions: Drug: Cisplatin; Drug: Gemcitabine; Biological: ALT-801
Sponsors: Altor Bioscience Corporation; Altor Bioscience Corporation; National Cancer Institute (NCI)
Recruiting - verified June 2013
Afatinib (BIBW2992) in HER2-overexpressing Inflammatory Breast Cancer

Condition: Breast Neoplasms
Interventions: Drug: Afatinib once daily (OD); Drug: Vinorelbine Weekly
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified June 2013
Eosinophilic Esophagitis Databank

Conditions: Esophagitis; Eosinophilic Esophagitis
Intervention:
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified May 2013
A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study

Condition: Hepatitis C
Intervention: Drug: TMC435
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified May 2013
A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer

Condition: Prostate Cancer Metastatic
Interventions: Biological: PROSTVAC-V; Biological: PROSTVAC-F; Drug: GM-CSF; Other: GM-CSF Placebo; Biological: Placebo
Sponsors: BN ImmunoTherapeutics; BN ImmunoTherapeutics
Recruiting - verified February 2013
Smoking Cessation Study In Healthy Adolescent Smokers

Condition: Smoking Cessation
Interventions: Drug: Varenicline 1mg BID; Drug: Varenicline 0.5mg BID; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves

Condition: Symptomatic Severe Aortic Stenosis
Interventions: Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: AVR with a surgical heart valve; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: AVR with a surgical heart valve; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis
Sponsors: Edwards Lifesciences; Edwards Lifesciences
Recruiting - verified May 2013
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Conditions: Prostate Cancer; Prostatic Neoplasm
Intervention: Drug: abiraterone acetate in combination with prednisone
Sponsors: Janssen Biotech, Inc.; Janssen Biotech, Inc.
Recruiting - verified May 2013
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Condition: Crohn's Disease
Interventions: Drug: GSK1605786A; Drug: Placebo; Drug: GSK1605786A
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
Open-Label Extension Study of GSK1605786A

Condition: Crohn's Disease
Intervention: Drug: GSK1605786A
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified June 2013
Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy

Conditions: Fungal Infection; Leukemia; Neutropenia
Interventions: Drug: caspofungin acetate; Drug: fluconazole
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2013
Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant

Condition: Bronchiolitis Obliterans
Interventions: Drug: fluticasone propionate; Drug: montelukast sodium; Procedure: pulmonary function testing; Other: questionnaire administration; Procedure: quality-of-life assessment; Other: laboratory biomarker analysis; Genetic: protein analysis; Drug: azithromycin
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified June 2013
A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases

Condition: HER-2 Positive Breast Cancer
Interventions: Drug: Everolimus; Drug: Vinorelbine; Drug: Trastuzumab
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; Novartis Pharmaceuticals
Recruiting - verified June 2013
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)

Condition: Warfarin Therapy
Intervention: Device: Warfarin GenoSTAT Test
Sponsors: Iverson Genetic Diagnostics, Inc.; Iverson Genetic Diagnostics, Inc.
Recruiting - verified May 2013
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

Condition: Depression
Interventions: Drug: Armodafinil; Drug: Placebo
Sponsors: Teva Pharmaceutical Industries; Cephalon
Recruiting - verified May 2013
INcrease Of VAgal TonE in CHF

Conditions: Left Ventricular Dysfunction; Heart Failure
Interventions: Device: CardioFit® System; Other: Standard of Care
Sponsors: BioControl Medical; BioControl Medical
Recruiting - verified May 2013
Safety of and Immune Response to GSK1349572 in HIV-1 Infected Infants, Children, and Adolescents

Condition: HIV Infections
Interventions: Drug: GSK1349572 tablet formulation; Drug: GSK1349572 oral pediatric granules taken as suspension or granules
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified June 2013
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Condition: Crohn's Disease
Interventions: Drug: PF-04236921 SC injection; Drug: PF-04236921 SC injection; Drug: PF-04236921 SC injection; Drug: PF-04236921 SC injection
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
A Study To Monitor Long-Term Treatment With PF-00547659

Condition: Crohn's Disease
Intervention: Drug: PF-00547659
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
Home Hypnotherapy for Refractory Functional Chest Pain: A Pilot Study

Condition: Functional Chest Pain
Interventions: Behavioral: Home Hypnotherapy; Behavioral: Educational
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified June 2013
Gulf Long-Term Follow-Up Study

Conditions: Cardiovascular Disease; Hematologic Diseases; Immunologic Disease; Cancer; Respiratory Function
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Environmental Health Sciences (NIEHS)
Recruiting - verified October 2012
TRINOVA-2: Trebananib in Ovarian Cancer-2

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cancer
Interventions: Drug: AMG386 plus PLD; Drug: Placebo plus PLD
Sponsors: Amgen; Amgen
Recruiting - verified June 2013
Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Condition: Crohn's Disease
Interventions: Drug: PF-00547659 SC injection; Drug: PF-00547659 SC injection; Drug: PF-00547659 SC injection; Drug: PF-00547659 SC injection
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
Impact of Blood Storage Duration on Physiologic Measures

Conditions: Cardiac Surgery; Erythrocyte Transfusion
Intervention:
Sponsors: Duke University; Duke University; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified June 2013
Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Metastatic Breast Cancer

Conditions: Breast Neoplasms; HER2 Protein, Human; Geriatric Health Services
Interventions: Drug: Lapatinib; Drug: Trastuzumab
Sponsors: City of Hope Medical Center; City of Hope Medical Center; GlaxoSmithKline; Genentech
Recruiting - verified June 2013
Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients With Postherpetic Neuralgia

Condition: Post Herpetic Neuralgia
Interventions: Drug: Pregabalin; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
A Randomized Trial of Medical and Surgical Treatments for Patients With GERD Symptoms That Are Refractory to Proton Pump Inhibitors

Condition: GERD
Interventions: Device: Nissen fundoplication; Drug: baclofen; Drug: Desipramine
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified May 2013
Manuka Honey in Preventing Esophagitis-Related Pain in Patients Receiving Chemotherapy and Radiation Therapy For Lung Cancer

Conditions: Dysphagia; Lung Cancer; Pain
Interventions: Drug: Manuka honey; Drug: chemotherapy; Other: questionnaire administration; Procedure: adjuvant therapy; Procedure: assessment of therapy complications; Procedure: quality-of-life assessment; Procedure: standard follow-up care; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
A Study of Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer

Condition: Pain
Interventions: Drug: Sativex®; Drug: Placebo (GA-0034)
Sponsors: GW Pharmaceuticals Ltd.; GW Pharmaceuticals Ltd.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified May 2011
Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus

Condition: Systemic Lupus Erythematosus
Interventions: Drug: Epratuzumab; Drug: Epratuzumab; Drug: Placebo
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified May 2013
Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)

Condition: Systemic Lupus Erythematosus
Interventions: Drug: Placebo; Drug: Epratuzumab; Drug: Epratuzumab
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified May 2013
Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures

Condition: Epilepsy
Interventions: Drug: Placebo; Drug: Brivaracetam; Drug: Brivaracetam
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified May 2013
Impact of Prevnar 13 on Ear Infections in Children

Conditions: Acute Otitis Media; Mastoiditis
Intervention:
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies

Conditions: Colorectal Neoplasms; Digestive System Diseases; Colonic Diseases; Colorectal Cancer
Intervention:
Sponsors: Exact Sciences Corporation; Exact Sciences Corporation
Recruiting - verified May 2013
Dysport® Adult Lower Limb Spasticity Study

Condition: Leg Spasticity
Interventions: Drug: Botulinum type A toxin (Dysport®); Drug: Placebo
Sponsors: Ipsen; Ipsen
Recruiting - verified May 2013
Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older

Conditions: Epilepsy; Monotherapy
Interventions: Drug: Lacosamide; Drug: Carbamazepine-Controlled Release
Sponsors: UCB, Inc.; UCB BIOSCIENCES GmbH; EDEV S.À.R.L
Recruiting - verified June 2013
A Study To Investigate The Safety And Possible Clinical Benefit Of Multistem(r) In Patients With Moderate To Severe Ulcerative Colitis

Condition: Colitis, Ulcerative
Interventions: Drug: placebo; Drug: MultiStem low dose; Drug: placebo; Drug: MultiStem low dose; Drug: placebo; Drug: MultiStem high dose; Drug: placebo; Drug: MultiStem high dose; Drug: placebo; Drug: MultiStem high dose; Drug: placebo; Drug: MultiStem high dose
Sponsors: Pfizer; Pfizer; Athersys, Inc
Recruiting - verified June 2013
A Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid Tumors

Condition: Solid Tumors
Interventions: Drug: LCL161; Drug: Paclitaxel
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified June 2013
Colonoscopy Versus Fecal Immunochemical Test in Reducing Mortality From Colorectal Cancer (CONFIRM)

Condition: Colorectal Cancer
Interventions: Procedure: Colonoscopy; Procedure: FIT
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified May 2013
Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections

Condition: Moderate Clostridium Difficile Infection
Interventions: Drug: LFF571; Drug: Vancomycin (POC)
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified June 2013
Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma

Conditions: Adult Supratentorial Primitive Neuroectodermal Tumor (PNET); Childhood Supratentorial Primitive Neuroectodermal Tumor; Ewing Sarcoma of Bone; Extraosseous Ewing Sarcoma; Extraosseous Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Peripheral Primitive Neuroectodermal Tumor of the Kidney; Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
Interventions: Drug: vincristine sulfate; Drug: doxorubicin hydrochloride; Drug: cyclophosphamide; Drug: ifosfamide; Drug: etoposide; Drug: topotecan hydrochloride; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza.

Condition: Influenza, Human
Interventions: Drug: 300mg intravenous (IV) zanamivir and oral oseltamivir placebo; Drug: 600mg intravenous (IV) zanamivir and oral oseltamivir placebo; Drug: 75mg oral oseltamivir and intravenous zanamivir placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified June 2013
Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications

Condition: Influenza
Interventions: Drug: Amantadine, Ribavirin, Oseltamivir; Drug: Oseltamivir
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2013
A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)

Condition: Cancer
Interventions: Drug: pazopanib; Drug: placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery

Condition: Head and Neck Cancer
Interventions: Drug: cisplatin; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer

Conditions: Prostate Neoplasms; Genital Neoplasms, Male; Urogenital Neoplasms; Genital Diseases, Male
Intervention: Drug: Abiraterone Acetate
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified June 2013
Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Sorafenib(Nexavar, BAY43-9006) / Capecitabine; Drug: Placebo / Capecitabine
Sponsors: Bayer; Bayer; Onyx Therapeutics, Inc.
Recruiting - verified June 2013
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65

Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Bortezomib; Drug: Dexamethasone; Procedure: Autologous Stem Cell Transplant
Sponsors: Dana-Farber Cancer Institute; Paul G. Richardson, MD; Celgene Corporation; Millennium Pharmaceuticals, Inc.; Massachusetts General Hospital; Cape Cod Healthcare; Beth Israel Deaconess Medical Center; Emory University; University of Michigan; Fox Chase Cancer Center; Memorial Sloan-Kettering Cancer Center; Fred Hutchinson Cancer Research Center; Barbara Ann Karmanos Cancer Institute; Duke University; University of California, San Francisco; University of Chicago; M.D. Anderson Cancer Center; UNC Lineberger Comprehensive Cancer Center; Roswell Park Cancer Institute; Stanford University; University of Mississippi Medical Center; Mount Sinai School of Medicine; Wake Forest University Baptist Medical Center
Recruiting - verified June 2013
Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke

Condition: Ischemic Stroke
Interventions: Drug: PF-03049423; Drug: PF-03049423; Drug: PF-03049423; Other: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
A Study of LY2127399 in Patients With Systemic Lupus Erythematosus

Conditions: Systemic Lupus Erythematosus; Connective Tissue Disease; Autoimmune Disease
Interventions: Drug: LY2127399; Drug: Placebo every 2 weeks; Drug: Placebo every 4 weeks
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013
Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects

Condition: Post Operative Pain
Intervention: Drug: oxymorphone HCl
Sponsors: Endo Pharmaceuticals; Endo Pharmaceuticals
Recruiting - verified May 2013
Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen

Condition: Hepatitis B Virus
Interventions: Drug: pegIFN; Drug: pegIFNα-2a; Drug: PegIFN lambda; Drug: Entecavir
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified June 2013
A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy

Condition: Diabetic Nephropathies
Interventions: Drug: PF-00489791; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy

Condition: Lymphoma, Follicular
Interventions: Biological: Ofatumumab; Biological: Rituximab
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
A Study of LY2127399 in Patients With Systemic Lupus Erythematosus

Conditions: Systemic Lupus Erythematosus; Connective Tissue Disease; Autoimmune Disease
Interventions: Drug: LY2127399; Drug: Placebo every 2 weeks; Drug: Placebo every 4 weeks
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013
Risk-Adapted Chemotherapy in Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: thioguanine; Drug: vincristine sulfate
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
Natural History Study of SCID Disorders

Conditions: SCID; Leaky SCID; Omenn Syndrome; Reticular Dysgenesis; ADA Deficiency; XSCID
Intervention:
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); Office of Rare Diseases (ORD)
Recruiting - verified May 2013
Pharmacokinetics of Tenofovir, Emtricitabine, Maraviroc, and Raltegravir in Cervical, Vaginal, and Rectal Tissues and Secretions

Condition: Healthy Adult Females
Intervention: Other: Pharmacokinetic Sampling
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill
Recruiting - verified May 2013
Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH-II)

Condition: Intracerebral Hemorrhage
Intervention: Drug: Nicardipine hydrochloride
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; Medical University of South Carolina; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified June 2013
A Study in Second Line Metastatic Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Biological: Ramucirumab; Drug: Irinotecan; Biological: Placebo; Drug: Folinic Acid; Drug: 5-Fluorouracil
Sponsors: Eli Lilly and Company; Eli Lilly and Company; ImClone LLC
Recruiting - verified June 2013
Changes in Performance Status and Symptom Distress in Older Patients With Advanced Ovarian Epithelial Cancer Undergoing Surgery and/or Chemotherapy

Condition: Ovarian Cancer
Interventions: Other: Palliative Performance Scale version 2 (PPSv2); Other: McCorkle Symptom Distress Scale (SDS); Other: Geriatric Assessment; Other: Medical Records Abstraction
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified June 2013
Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

Conditions: Light Chain Deposition Disease; Smoldering Multiple Myeloma
Interventions: Other: clinical observation; Drug: lenalidomide; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

Condition: Hypertension, Pulmonary
Interventions: Drug: ambrisentan; Drug: tadalafil
Sponsors: GlaxoSmithKline; GlaxoSmithKline; Gilead Sciences
Recruiting - verified May 2013
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

Condition: Psoriasis
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer

Condition: Neoplasms, Breast
Interventions: Drug: lapatinib; Drug: trastuzumab; Drug: Aromatase inhibitor; Drug: lapatinib
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia

Conditions: Childhood Hepatoblastoma; Previously Treated Childhood Rhabdomyosarcoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Malignant Germ Cell Tumor; Recurrent Childhood Rhabdomyosarcoma; Recurrent Childhood Soft Tissue Sarcoma; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Neuroblastoma; Recurrent Osteosarcoma; Recurrent Wilms Tumor and Other Childhood Kidney Tumors
Interventions: Drug: alisertib; Other: pharmacological study; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
Study to Assess Efficacy and Safety of Anti-von Willebrand Factor Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (TTP)

Condition: Thrombotic Thrombocytopenic Purpura
Interventions: Biological: anti-vWF Nanobody; Biological: Placebo
Sponsors: Ablynx; Ablynx
Recruiting - verified June 2013
Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)

Condition: Acute Coronary Syndrome
Interventions: Drug: lixisenatide (AVE0010); Drug: placebo
Sponsors: Sanofi; Sanofi
Recruiting - verified June 2013
A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects

Condition: Smallpox
Interventions: Biological: IMVAMUNE; Biological: IMVAMUNE; Biological: IMVAMUNE; Other: Placebo
Sponsors: Bavarian Nordic; Bavarian Nordic
Recruiting - verified May 2013
The Role of Glucocorticoid Receptor SNPs in Receptor Function and Metabolic Disease

Conditions: Glucose Homeostasis; Protein Metabolism; Lipid Metabolism; Respiratory Function; Connective Tissue Metabolism
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Environmental Health Sciences (NIEHS)
Recruiting - verified December 2012
Study of the Effect of SNPs in p53 and p53 Response Elements on the Inflammatory Response to DNA Damage

Conditions: Inflammation; Cancer; Cardiomyopathy
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Environmental Health Sciences (NIEHS)
Recruiting - verified February 2013
Efficacy and Safety of Adalimumab in Subjects With Active Uveitis

Condition: Uveitis
Interventions: Drug: adalimumab; Drug: prednisone; Drug: adalimumab placebo; Drug: prednisone
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified April 2013
Efficacy and Safety of Adalimumab in Subjects With Inactive Uveitis

Condition: Uveitis
Interventions: Drug: adalimumab; Drug: prednisone; Drug: prednisone; Drug: adalimumab placebo
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified April 2013
A Study to Determine if There is a Possible Association Between Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) and Phosphodiesterase Type 5 (PDE5) Inhibitors

Condition: Nonarteritic Anterior Ischemic Optic Neuropathy
Intervention: Drug: PDE5 Inhibitors
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013
Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma

Condition: Lymphoma
Interventions: Biological: bleomycin sulfate; Drug: ABVD regimen; Drug: BEACOPP regimen; Drug: cyclophosphamide; Drug: dacarbazine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: prednisone; Drug: procarbazine hydrochloride; Drug: vinblastine sulfate; Drug: vincristine sulfate; Other: laboratory biomarker analysis; Procedure: computed tomography; Radiation: fludeoxyglucose F 18; Radiation: radiation therapy
Sponsors: Alliance for Clinical Oncology Trials; Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified June 2013
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension

Condition: Pulmonary Arterial Hypertension
Interventions: Drug: imatinib; Drug: imatinib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified June 2013
A Study in Patients With Diabetic Kidney Disease

Conditions: Diabetic Kidney Disease; Diabetic Nephropathy; Diabetic Glomerulosclerosis
Interventions: Drug: LY2382770; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013
Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801)

Condition: Chronic GVHD
Interventions: Drug: Sirolimus + calcineurin inhibitor + prednisone; Drug: Sirolimus + prednisone
Sponsors: Medical College of Wisconsin; Medical College of Wisconsin; National Heart, Lung, and Blood Institute (NHLBI); National Cancer Institute (NCI); Blood and Marrow Transplant Clinical Trials Network
Recruiting - verified May 2013
Patient Registry Study of Berinert® in Normal Clinical Practice

Condition: Includes: Hereditary Angioedema
Intervention: Biological: Berinert® (C1 Esterase Inhibitor)
Sponsors: CSL Behring; CSL Behring; Chiltern International Inc.
Recruiting - verified May 2013
Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor

Condition: Gastric Cancer
Intervention: Drug: Veliparib
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified May 2013
Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Condition: Cardiovascular Disease
Interventions: Drug: Febuxostat; Drug: Allopurinol
Sponsors: Takeda; Takeda
Recruiting - verified June 2013
Ursodiol in Treating Patients With Barrett Esophagus and Low-Grade Dysplasia

Conditions: Barrett Esophagus; Esophageal Cancer
Interventions: Drug: ursodiol; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified June 2013
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma

Conditions: Childhood Infratentorial Ependymoma; Childhood Supratentorial Ependymoma; Newly Diagnosed Childhood Ependymoma
Interventions: Drug: liposomal vincristine sulfate; Other: clinical observation; Radiation: 3-dimensional conformal radiation therapy; Drug: carboplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: cisplatin; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
Study in Head and Neck Cancer

Condition: Head and Neck Neoplasms
Interventions: Drug: Cetuximab; Drug: Cisplatin; Drug: 5 - Fluorouracil
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013
Sample Collection Registry for Quality Control of Biological and Environmental Specimens and Assay Development and Testing

Condition: Biospecimen
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Environmental Health Sciences (NIEHS)
Recruiting - verified November 2012
Radiation Therapy in Treating Women With Locally Recurrent Breast Cancer Previously Treated With Repeat Breast-Preserving Surgery

Condition: Breast Cancer
Interventions: Other: circulating tumor cell analysis; Other: laboratory biomarker analysis; Other: questionnaire administration; Procedure: adjuvant therapy; Radiation: 3-dimensional conformal accelerated partial breast irradiation
Sponsors: Radiation Therapy Oncology Group; Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)

Conditions: Chronic Myeloid Leukemia; Acute Lymphoblastic Leukemia
Intervention: Drug: Nilotinib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013
Immunotherapy Study for Surgically Resected Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Biological: HyperAcute-Pancreas Immunotherapy; Drug: Gemcitabine; Radiation: 5FU Chemoradiation
Sponsors: NewLink Genetics Corporation; NewLink Genetics Corporation
Recruiting - verified June 2013
Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption

Condition: HIV Infection
Interventions: Biological: AGS-004; Biological: Placebo
Sponsors: Argos Therapeutics; Argos Therapeutics
Recruiting - verified June 2013
Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: everolimus; Drug: temozolomide; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
Simvastatin Therapy for Moderate and Severe COPD

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: simvastatin; Drug: Placebo
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified June 2013
Long-Term Outcomes in HIV-Infected Infants, Children, and Adolescents

Condition: HIV Infections
Intervention:
Sponsors: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; International Maternal Pediatric Adolescent AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified June 2013
INSIGHT Influenza Hospitalization Study (FLU 003)

Conditions: Influenza; (Influenza A and Subtypes Such as H3N2 and 2009 H1N1 or Influenza B)
Intervention:
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; National Institute of Allergy and Infectious Diseases (NIAID); National Institutes of Health (NIH)
Recruiting - verified June 2013
INSIGHT Influenza Outpatient Study (FLU 002)

Condition: Influenza
Intervention:
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; National Institute of Allergy and Infectious Diseases (NIAID); National Institutes of Health (NIH)
Recruiting - verified June 2013
Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy

Condition: Leukaemia, Lymphocytic, Chronic
Interventions: Biological: Ofatumumab; Other: Observation
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified June 2013
Memantine and Postoperative Pain

Condition: Pain
Interventions: Drug: Memantine; Drug: Placebo
Sponsors: Duke University; Duke University
Recruiting - verified May 2013
Refinement of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Via Cognitive Interviewing and Usability Testing

Conditions: Adverse Events; Usability Testing; Cognitive Testing
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified August 2012
Donor Lymphocyte Infusion After Alternative Donor Transplantation

Condition: Immunocompromised After T-cell Depleted Transplant.
Intervention: Biological: Infusion of donor lymphocytes
Sponsors: Carolinas Healthcare System; Andrew Gilman
Recruiting - verified May 2013
Adolescent Fibromyalgia Study

Condition: Fibromyalgia
Interventions: Drug: placebo; Drug: pregabalin (Lyrica)
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Trial of Late Surfactant for Prevention of Bronchopulmonary Dysplasia

Condition: Bronchopulmonary Dysplasia
Intervention: Drug: Infasurf surfactant (ONY, Inc.)
Sponsors: University of California, San Francisco; University of California, San Francisco; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified May 2013
Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma

Conditions: Recurrent Uterine Sarcoma; Stage IIIA Uterine Sarcoma; Stage IIIB Uterine Sarcoma; Stage IIIC Uterine Sarcoma; Stage IVA Uterine Sarcoma; Stage IVB Uterine Sarcoma; Uterine Leiomyosarcoma
Interventions: Other: placebo; Biological: bevacizumab; Drug: gemcitabine hydrochloride; Drug: docetaxel; Biological: filgrastim; Biological: pegfilgrastim
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

Conditions: Adult Primary Hepatocellular Carcinoma; Advanced Adult Primary Liver Cancer; Endometrial Papillary Serous Carcinoma; Localized Unresectable Adult Primary Liver Cancer; Metastatic Gastrointestinal Carcinoid Tumor; Ovarian Carcinosarcoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mixed Epithelial Carcinoma; Ovarian Papillary Serous Carcinoma; Pancreatic Alpha Cell Adenoma; Pancreatic Alpha Cell Carcinoma; Pancreatic Beta Islet Cell Adenoma; Pancreatic Beta Islet Cell Carcinoma; Pancreatic Delta Cell Adenoma; Pancreatic Delta Cell Carcinoma; Pancreatic G-cell Adenoma; Pancreatic G-cell Carcinoma; Pancreatic Polypeptide Tumor; Pulmonary Carcinoid Tumor; Recurrent Adult Primary Liver Cancer; Recurrent Endometrial Carcinoma; Recurrent Fallopian Tube Cancer; Recurrent Gastrointestinal Carcinoid Tumor; Recurrent Islet Cell Carcinoma; Recurrent Ovarian Epithelial Cancer; Recurrent Primary Peritoneal Cavity Cancer; Regional Gastrointestinal Carcinoid Tumor; Stage IIIA Endometrial Carcinoma; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Epithelial Cancer; Stage IIIA Primary Peritoneal Cavity Cancer; Stage IIIB Endometrial Carcinoma; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Epithelial Cancer; Stage IIIB Primary Peritoneal Cavity Cancer; Stage IIIC Endometrial Carcinoma; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Epithelial Cancer; Stage IIIC Primary Peritoneal Cavity Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Epithelial Cancer; Stage IV Primary Peritoneal Cavity Cancer; Stage IVA Endometrial Carcinoma; Stage IVB Endometrial Carcinoma; Uterine Carcinosarcoma
Interventions: Drug: temsirolimus; Biological: bevacizumab
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified June 2013
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma

Condition: Lymphoma, Large-Cell, Diffuse
Interventions: Drug: OFATUMUMAB + DHAP; Drug: RITUXIMAB + DHAP
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified June 2013
Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)

Condition: Refractory Cutaneous T-cell Lymphoma
Interventions: Drug: bexarotene; Drug: bexarotene
Sponsors: Valeant Pharmaceuticals International, Inc.; Valeant Pharmaceuticals International, Inc.
Recruiting - verified June 2013
Red Cell Storage Duration Study

Conditions: Cardiac Surgery; Erythrocyte Transfusion
Interventions: Biological: Red blood cell units stored <= 10 days; Biological: Red blood cell units stored >= 21 days
Sponsors: New England Research Institutes; New England Research Institutes; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified May 2013
Lymphedema Following Hand/Wrist Surgery in Women Post Axillary Node Dissection

Condition: Lymphedema
Intervention: Procedure: Tourniquet Use
Sponsors: OrthoCarolina Research Institute, Inc.; OrthoCarolina Research Institute, Inc.
Recruiting - verified January 2012
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Liver Cancer

Conditions: Childhood Hepatoblastoma; Stage I Childhood Liver Cancer; Stage II Childhood Liver Cancer; Stage III Childhood Liver Cancer; Stage IV Childhood Liver Cancer
Interventions: Procedure: therapeutic conventional surgery; Drug: cisplatin; Drug: fluorouracil; Drug: vincristine sulfate; Drug: doxorubicin hydrochloride; Drug: irinotecan hydrochloride; Procedure: liver transplantation; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults

Condition: HIV Infections
Interventions: Drug: Raltegravir (RAL); Drug: Atazanavir (ATV); Drug: Ritonavir (RTV); Drug: Tenofovir (TDF); Drug: Etravirine (ETV); Drug: Darunavir (DRV); Drug: Maraviroc (MVC); Drug: Lopinavir/ritonavir (LPV/r)
Sponsors: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; International Maternal Pediatric Adolescent AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified June 2013
T-cell Depleted Alternative Donor Transplantation

Conditions: Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Chronic Myeloid Leukemia; Myelodysplastic Syndrome; Lymphomas; Bone Marrow Failure; Hemoglobinopathy; Immune Deficiency; Osteopetrosis
Intervention: Device: CliniMACS® (T cell depletion)
Sponsors: Carolinas Healthcare System; Andrew Gilman
Recruiting - verified May 2013
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

Condition: Cancer
Interventions: Drug: Lapatinib; Biological: Trastuzumab
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer

Condition: Head and Neck Cancer
Interventions: Biological: cetuximab; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
Examining Benefits of HAART Continuation in Postpartum Mothers

Condition: HIV Infections
Intervention: Drug: Highly active antiretroviral therapy (HAART)
Sponsors: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; International Maternal Pediatric Adolescent AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified June 2013
Ankle Block Versus Popliteal Fossa Block as Primary Anesthesia for Forefoot Surgical Procedures

Conditions: Anesthesia; Forefoot Surgery
Intervention: Procedure: elective forefoot surgery
Sponsors: OrthoCarolina Research Institute, Inc.; OrthoCarolina Research Institute, Inc.
Recruiting - verified January 2012
Stem Cell Related Donor Safety Study

Condition: Related Hematopoietic Stem Cell Donors
Intervention:
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; National Institutes of Health (NIH); University of Utah; University of Pittsburgh
Recruiting - verified May 2013
Enhanced Self-Efficacy Training

Condition: Neoplasms
Interventions: Other: Self-Efficacy Training for Caregivers; Other: Comparison Conditions for Caregivers
Sponsors: Duke University; Duke University; National Institute of Nursing Research (NINR)
Recruiting - verified May 2013
Lidocaine For Neuroprotection During Cardiac Surgery

Condition: Cognitive Decline
Interventions: Drug: Lidocaine; Drug: Placebo
Sponsors: Duke University; Duke University; National Institutes of Health (NIH); CAS Medical Systems, Inc.
Recruiting - verified June 2013
A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Patients With Advanced Breast Cancer

Condition: Breast Cancer
Interventions: Drug: trastuzumab emtansine; Drug: docetaxel; Drug: pertuzumab
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified June 2013
A Multicenter, Open-Label Study To Investigate The Safety And Pharmacokinetics Of Lacosamide In Children With Partial Seizures

Condition: Epilepsy
Intervention: Drug: Lacosamide
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified May 2013
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: PF-02341066
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
A Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Cancer-related Pain

Conditions: Pain, Burning; Pain, Crushing; Pain, Migratory; Pain, Radiating; Pain, Splitting
Interventions: Drug: JNJ-42160443; Drug: Placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified June 2013
Continuous Oral Contraceptive Treatment in Premenstrual Dysphoric Disorder (PMDD)

Condition: Premenstrual Dysphoric Disorder
Interventions: Drug: low dose oral contraceptive (20 ug ethinyl estradiol + 3 mg drospirenone); Drug: 20 ug ethinyl estradiol + 3 mg drospirenone; Drug: placebo
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill
Recruiting - verified June 2013
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Conditions: Cancer; Cataract; Low Bone Mineral Density; Osteopenia; Osteoporosis; Prostate Cancer
Interventions: Biological: Denosumab; Biological: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified June 2013
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma

Conditions: Adult Rhabdomyosarcoma; Childhood Desmoplastic Small Round Cell Tumor; Chordoma; Desmoid Tumor; Metastatic Childhood Soft Tissue Sarcoma; Nonmetastatic Childhood Soft Tissue Sarcoma; Previously Treated Childhood Rhabdomyosarcoma; Previously Untreated Childhood Rhabdomyosarcoma; Recurrent Adult Soft Tissue Sarcoma; Recurrent Childhood Rhabdomyosarcoma; Recurrent Childhood Soft Tissue Sarcoma; Stage I Adult Soft Tissue Sarcoma; Stage II Adult Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage IV Adult Soft Tissue Sarcoma
Interventions: Other: biologic sample preservation procedure; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)

Condition: Glioblastoma Multiforme
Interventions: Device: NovoTTF-100A device; Drug: Temozolomide
Sponsors: NovoCure Ltd.; NovoCure Ltd.
Recruiting - verified May 2013
Oral Metolazone and Intermittent Intravenous Furosemide Versus Continuous Infusion Furosemide in Acute Heart Failure

Condition: Acute Decompensated Heart Failure
Interventions: Drug: Intravenous Bolus Furosemide and Oral Metolazone; Drug: Intravenous Continuous Infusion Furosemide
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; University of Illinois
Recruiting - verified May 2013
Study Evaluating A Planned Transition From Tacrolimus To Sirolimus In Kidney Transplant Recipients

Conditions: Graft Rejection; Kidney Transplant; Renal Allograft Recipients; Renal Transplant
Interventions: Drug: Tacrolimus; Drug: Sirolimus; Drug: Tacrolimus
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
A Study That Will Compare the Effect of Two Drugs on Participants With Low Bone Mass and a Recent Hip Fracture

Condition: Osteoporosis
Interventions: Drug: Teriparatide; Drug: Risedronate; Drug: Placebo; Dietary Supplement: Calcium; Dietary Supplement: Vitamin D
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013
N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma

Condition: Neuroblastoma
Interventions: Drug: Bevacizumab; Drug: cyclophosphamide; Drug: zoledronic acid
Sponsors: New Approaches to Neuroblastoma Therapy Consortium; New Approaches to Neuroblastoma Therapy Consortium; National Cancer Institute (NCI)
Recruiting - verified June 2013
Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Conditions: Leukemia; Lymphoma
Interventions: Biological: filgrastim; Drug: asparaginase; Drug: bortezomib; Drug: cyclophosphamide; Drug: cytarabine; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: leucovorin calcium; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
PDE5 Inhibitor Use and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)

Condition: Anterior Ischemic Optic Neuropathy
Intervention: Drug: Diagnostic procedures
Sponsors: Bayer; Bayer
Recruiting - verified May 2013
Strategic Timing of Antiretroviral Treatment

Condition: HIV Infection
Intervention: Drug: All licensed antiretroviral medications
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; National Institute of Allergy and Infectious Diseases (NIAID); Copenhagen HIV Programme (CHIP) -- Copenhagen, Denmark; Medical Research Council (MRC) Clinical Trials Unit -- London, United Kingdom; The Kirby Institute for Infection and Immunity in Society; The Institute for Clinical Research at the Veterans Affairs Medical Center -- Washington, D.C., USA; French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS); German Federal Ministry of Education and Research; NEAT - European AIDS Treatment Network; National Health and Medical Research Council, Australia; National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI); National Heart, Lung, and Blood Institute (NHLBI); National Institute of Mental Health (NIMH); National Institute of Neurological Disorders and Stroke (NINDS); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Abbott; Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Merck; Tibotec Pharmaceutical Limited
Recruiting - verified June 2013
International Study to Predict Optimised Treatment in Attention Deficit/Hyperactivity Disorder

Condition: Attention Deficit/Hyperactivity Disorder
Interventions: Drug: Short Acting Methylphenidate; Drug: Long Acting Methylphenidate
Sponsors: BRC Operations Pty. Ltd.; BRC Operations Pty. Ltd.
Recruiting - verified June 2013
A Study to Assess the Pharmacokinetics (Blood Levels) of TMC114 (Darunavir) Taken With Ritonavir and/or TMC125 (Etravirine) and TMC278 (Rilpivirine) in HIV-1 Infected Pregnant Women

Conditions: HIV; HIV Infections; Pregnancy
Interventions: Drug: TMC114 (darunavir); Drug: ritonavir; Drug: TMC125 (etravirine); Drug: TMC278 (rilpivirine); Drug: TMC114 (darunavir)
Sponsors: Tibotec, Inc; Tibotec, Inc; Janssen Services, LLC
Recruiting - verified June 2013
Study to Compare the Efficacy and Safety of Micafungin Versus Conventional Amphotericin B for the Treatment of Neonatal Candidiasis

Condition: Candidiasis
Interventions: Drug: micafungin; Drug: amphotericin B deoxycholate
Sponsors: Astellas Pharma Inc; Astellas Pharma Global Development, Inc.
Recruiting - verified June 2013
Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia

Conditions: Adult Acute Lymphoblastic Leukemia in Remission; B-cell Adult Acute Lymphoblastic Leukemia; L1 Adult Acute Lymphoblastic Leukemia; L2 Adult Acute Lymphoblastic Leukemia; Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; T-cell Adult Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia
Interventions: Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: vincristine sulfate; Drug: dexamethasone; Drug: dasatinib; Drug: cytarabine; Drug: methotrexate; Biological: filgrastim; Drug: methylprednisolone; Drug: leucovorin calcium; Drug: prednisone; Radiation: total-body irradiation; Drug: etoposide; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Drug: sirolimus; Drug: tacrolimus; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified June 2013
Community Cancer Centers Pilot Patient Survey

Condition: Malignant Neoplasms
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified July 2012
Filgrastim-Mobilized Stem Cells for Transplantation Using Unrelated Donors

Condition: Healthy
Intervention: Drug: Filgrastim
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; National Marrow Donor Program
Recruiting - verified May 2013
Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage Phase III

Condition: Intraventricular Hemorrhage
Interventions: Drug: Cathflo Activase; Other: Normal saline
Sponsors: Johns Hopkins University; Daniel Hanley; National Institute of Neurological Disorders and Stroke (NINDS); Genentech; Emissary International LLC
Recruiting - verified June 2013
Neuropsychological and Behavioral Testing in Young Patients With Cancer

Conditions: Chemotherapeutic Agent Toxicity; Cognitive/Functional Effects; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment; Radiation Toxicity; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Other: questionnaire administration; Procedure: cognitive assessment; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
Lenalidomide With or Without Rituximab After Standard Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma

Condition: Lymphoma
Interventions: Drug: Lenalidomide; Drug: Lenalidomide; Drug: Rituximab
Sponsors: Vanderbilt-Ingram Cancer Center; Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified June 2013
Study To Assess The Safety, Pharmacokinetics, And Evaluate The Response To Anidulafungin When Treating Children With Invasive Candidiasis

Conditions: Candidemia; Candidiasis
Interventions: Drug: anidulafungin; Drug: fluconazole
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer

Condition: Lung Cancer
Intervention: Radiation: stereotactic body radiation therapy (SBRT)
Sponsors: Radiation Therapy Oncology Group; Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
Evaluating the Safety and Effectiveness of Bone Marrow Transplants in Children With Sickle Cell Disease (BMT CTN #0601) (The SCURT Study)

Condition: Sickle Cell Disease
Intervention: Biological: Hematopoietic Stem Cell Transplantation
Sponsors: Medical College of Wisconsin; Medical College of Wisconsin; National Heart, Lung, and Blood Institute (NHLBI); Blood and Marrow Transplant Clinical Trials Network; National Cancer Institute (NCI); National Marrow Donor Program; Sickle Cell Disease Clinical Research Network
Recruiting - verified May 2013
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Acute Myeloid Leukemia/Transient Myeloproliferative Disorder; Acute Undifferentiated Leukemia; Angioimmunoblastic T-cell Lymphoma; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blastic Phase Chronic Myelogenous Leukemia; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Burkitt Lymphoma; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Grade III Lymphomatoid Granulomatosis; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Chronic Eosinophilic Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; Cutaneous B-cell Non-Hodgkin Lymphoma; Essential Thrombocythemia; Extramedullary Plasmacytoma; Intraocular Lymphoma; Isolated Plasmacytoma of Bone; Juvenile Myelomonocytic Leukemia; Long-term Effects Secondary to Cancer Therapy in Children; Mast Cell Leukemia; Meningeal Chronic Myelogenous Leukemia; Monoclonal Gammopathy of Undetermined Significance; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Polycythemia Vera; Post-transplant Lymphoproliferative Disorder; Primary Central Nervous System Hodgkin Lymphoma; Primary Central Nervous System Non-Hodgkin Lymphoma; Primary Myelofibrosis; Primary Systemic Amyloidosis; Progressive Hairy Cell Leukemia, Initial Treatment; Prolymphocytic Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Stage 0 Chronic Lymphocytic Leukemia; Stage I Childhood Anaplastic Large Cell Lymphoma; Stage I Childhood Hodgkin Lymphoma; Stage I Childhood Large Cell Lymphoma; Stage I Childhood Lymphoblastic Lymphoma; Stage I Childhood Small Noncleaved Cell Lymphoma; Stage I Chronic Lymphocytic Leukemia; Stage I Cutaneous T-cell Non-Hodgkin Lymphoma; Stage I Multiple Myeloma; Stage I Mycosis Fungoides/Sezary Syndrome; Stage II Childhood Anaplastic Large Cell Lymphoma; Stage II Childhood Hodgkin Lymphoma; Stage II Childhood Large Cell Lymphoma; Stage II Childhood Lymphoblastic Lymphoma; Stage II Childhood Small Noncleaved Cell Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Cutaneous T-cell Non-Hodgkin Lymphoma; Stage II Multiple Myeloma; Stage II Mycosis Fungoides/Sezary Syndrome; Stage III Childhood Anaplastic Large Cell Lymphoma; Stage III Childhood Hodgkin Lymphoma; Stage III Childhood Large Cell Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage III Childhood Small Noncleaved Cell Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Cutaneous T-cell Non-Hodgkin Lymphoma; Stage III Multiple Myeloma; Stage III Mycosis Fungoides/Sezary Syndrome; Stage IV Childhood Anaplastic Large Cell Lymphoma; Stage IV Childhood Hodgkin Lymphoma; Stage IV Childhood Large Cell Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Stage IV Childhood Small Noncleaved Cell Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IV Mycosis Fungoides/Sezary Syndrome; T-cell Large Granular Lymphocyte Leukemia; Unspecified Childhood Solid Tumor, Protocol Specific; Untreated Childhood Acute Lymphoblastic Leukemia; Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies; Untreated Hairy Cell Leukemia; Waldenström Macroglobulinemia
Interventions: Other: survey administration; Procedure: assessment of therapy complications; Procedure: long-term screening; Procedure: study of high risk factors
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
International Study to Predict Optimised Treatment - in Depression

Condition: Major Depressive Disorder
Interventions: Drug: Escitalopram; Drug: Sertraline; Drug: Venlafaxine XR
Sponsors: BRC Operations Pty. Ltd.; BRC Operations Pty. Ltd.
Recruiting - verified June 2013
Bacterial Vaginosis Home Screening to Prevent STDs

Condition: Bacterial Vaginosis
Intervention: Drug: Metronidazole
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2013
Prospective Observational Epidemiologic Study of Maraviroc's Safety

Condition: Human Immunodeficiency Virus
Interventions: Drug: Maraviroc along with an optimized background antiretroviral drug regimen; Drug: Optimized background antiretroviral drug regimen without maraviroc
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Recruiting - verified May 2013
Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients

Condition: Kidney Transplantation
Interventions: Drug: Cyclosporine; Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Evaluate Safety of T/I on Diabetic Subjects With Mild Obstructive Pulmonary Disease

Conditions: Diabetic Type 1 With Obstructive Pulmonary Disease; Diabetic Type 2 With Obstructive Pulmonary Disease; Asthma; COPD; Type 1 Diabetes; Type 2 Diabetes; Indeterminate Obstructive Lung Disease
Interventions: Drug: Technosphere Insulin; Drug: Usual Care
Sponsors: Mannkind Corporation; Mannkind Corporation
Recruiting - verified May 2013
Outcomes of Nursing Management Practice in Nursing Homes

Condition: Accidental Falls
Interventions: Behavioral: Falls QI; Behavioral: Connect
Sponsors: Duke University; Duke University; The Carolinas Center for Medical Excellence
Recruiting - verified June 2013
Three Different Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide

Condition: Lung Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy; Drug: cisplatin; Drug: etoposide
Sponsors: Alliance for Clinical Oncology Trials; Cancer and Leukemia Group B; National Cancer Institute (NCI); Radiation Therapy Oncology Group; Eastern Cooperative Oncology Group; North Central Cancer Treatment Group; Southwestern Oncology Group (SWOG)
Recruiting - verified June 2013
A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Conditions: Crohn's Disease; Ulcerative Colitis; Indeterminate Colitis; Inflammatory Bowel Diseases
Interventions: Biological: Anti TNF therapy including infliximab; Drug: No Biologics
Sponsors: Janssen Biotech, Inc.; Janssen Biotech, Inc.
Recruiting - verified June 2013
Statin Therapy Versus Placebo Prior to Prostatectomy

Conditions: Cancer; Prostate
Interventions: Drug: Simvastatin; Other: Placebo
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs; Oregon Health and Science University
Recruiting - verified May 2013
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: flutamide; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; Radiation Therapy Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified June 2013
Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma

Condition: Extraocular Retinoblastoma
Interventions: Procedure: autologous bone marrow transplantation; Procedure: autologous hematopoietic stem cell transplantation; Procedure: in vitro-treated peripheral blood stem cell transplantation; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Biological: filgrastim; Drug: carboplatin; Drug: vincristine sulfate; Drug: thiotepa; Radiation: radiation therapy
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia

Condition: Leukemia
Interventions: Biological: anti-thymocyte globulin; Drug: busulfan; Drug: cyclophosphamide; Drug: cyclosporine; Drug: methotrexate; Drug: methylprednisolone; Drug: tacrolimus; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: allogeneic bone marrow transplantation; Procedure: allogeneic hematopoietic stem cell transplantation
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2013
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.

Condition: Influenza
Interventions: Drug: oseltamivir; Drug: oseltamivir; Other: Alternative Control
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified June 2013
Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine

Condition: Influenza
Interventions: Biological: 13 valent pneumococcal conjugate vaccine; Biological: 13 valent pneumococcal conjugate vaccine
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
Psoriasis Longitudinal Assessment and Registry (PSOLAR)

Conditions: Psoriasis; Arthritis, Psoriatic
Interventions: Biological: ustekinumab; Biological: Biological therapies other than infliximab and ustekinumab; Drug: conventional systemic agents; Biological: infliximab
Sponsors: Centocor Ortho Biotech Services, L.L.C.; Centocor Ortho Biotech Services, L.L.C.
Recruiting - verified June 2013
Open-Label Extension Study Of Safety And Tolerability Of Pregabalin In Pediatric Patients With Partial-Onset Seizures

Condition: Epilepsies, Partial
Intervention: Drug: Pregabalin
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis

Condition: Arthritis, Rheumatoid
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
A Pivotal Study of a Facet Replacement System to Treat Spinal Stenosis

Condition: Lumbar Spinal Stenosis
Interventions: Device: ACADIA® Facet Replacement System; Device: Instrumented posterolateral fusion
Sponsors: Globus Medical Inc; Globus Medical Inc
Recruiting - verified June 2013
Immune Cell Response to Stimuli

Condition: Healthy
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Environmental Health Sciences (NIEHS)
Recruiting - verified April 2013
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor

Conditions: Untreated Childhood Medulloblastoma; Untreated Childhood Pineoblastoma; Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
Interventions: Drug: carboplatin; Drug: cyclophosphamide; Biological: filgrastim; Drug: cisplatin; Drug: isotretinoin; Drug: vincristine sulfate; Radiation: radiation therapy; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
Repository for Inherited Eye Diseases

Conditions: Retinitis Pigmentosa; Inherited Ophthalmic Diseases
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Eye Institute (NEI)
Recruiting - verified May 2013
A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer

Condition: Kidney Neoplasms
Interventions: Drug: Sunitinib malate; Other: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor

Conditions: Stage I Wilms Tumor; Stage II Wilms Tumor; Stage III Wilms Tumor
Interventions: Procedure: therapeutic conventional surgery; Drug: vincristine sulfate; Biological: dactinomycin; Drug: doxorubicin hydrochloride; Radiation: 3-dimensional conformal radiation therapy
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo

Condition: Epilepsies, Partial
Interventions: Drug: Lyrica (pregabalin); Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen

Conditions: Arthritis, Rheumatoid; Osteoarthritis
Interventions: Drug: celecoxib; Drug: Ibuprofen; Drug: Naproxen
Sponsors: Pfizer; Pfizer; The Cleveland Clinic
Recruiting - verified June 2013
UCB Antiepileptic Drugs (AED) Pregnancy Registry (Formerly the Keppra® Pregnancy Registry)

Conditions: Birth Defects; Pregnancy Complications; Epilepsy; Seizures
Intervention:
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified May 2013
Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors

Condition: Kidney Cancer
Interventions: Biological: dactinomycin; Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: irinotecan hydrochloride; Drug: vincristine sulfate; Procedure: therapeutic conventional surgery; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma

Conditions: Untreated Childhood Medulloblastoma; Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
Interventions: Drug: etoposide; Drug: cyclophosphamide; Drug: cisplatin; Biological: filgrastim; Drug: carboplatin; Drug: thiotepa; Drug: methotrexate; Drug: leucovorin calcium; Drug: vincristine sulfate; Procedure: autologous hematopoietic stem cell transplantation; Other: laboratory biomarker analysis; Procedure: quality-of-life assessment
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
Fludarabine-based Conditioning for Severe Aplastic Anemia

Condition: Anemia, Aplastic
Interventions: Drug: Cyclophosphamide; Drug: Cyclophosphamide; Drug: Cyclophosphamide; Drug: Cyclophosphamide
Sponsors: Medical College of Wisconsin; Medical College of Wisconsin; National Heart, Lung, and Blood Institute (NHLBI); Blood and Marrow Transplant Clinical Trials Network; National Cancer Institute (NCI)
Recruiting - verified June 2013
Efficacy and Safety of Vanquix for the Management of Selected, Refractory, Patients With Epilepsy Who Require Intermittent Caregiver Medical Intervention to Control Episodes of Acute Repetitive Seizures.

Conditions: Seizures; Epilepsies, Partial; Epilepsy, Complex Partial; Epilepsy, Generalized; Epilepsy
Interventions: Drug: Placebo; Drug: Vanquix Auto-Injector (Diazepam Injection)
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Virulence Determinants in S Aureus Bacteremia

Condition: Bacteremia
Intervention: Other: No intervention
Sponsors: Duke University; Duke University; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2013
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)

Condition: Melanoma
Interventions: Procedure: Completion Lymphadenectomy; Procedure: Monitoring with nodal ultrasound
Sponsors: John Wayne Cancer Institute; John Wayne Cancer Institute; National Institutes of Health (NIH)
Recruiting - verified June 2013
Compassionate Use of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES)

Condition: Hypereosinophilic Syndrome
Intervention: Drug: mepolizumab
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma

Conditions: Brain Tumor; Central Nervous System Tumor
Interventions: Drug: cisplatin; Drug: cyclophosphamide; Drug: lomustine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
Study of Late-Occurring Complications in Childhood Cancer Survivors

Conditions: Cancer Survivor; Cardiovascular Complications; Hematopoietic/Lymphoid Cancer; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Other: questionnaire administration; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
Emergency Use Program for HTE HIV+ Patients Who Need Tipranavir Treatment

Condition: HIV Infections
Intervention: Drug: Tipranavir
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Available - verified June 2013
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer

Conditions: Glioblastoma Multiforme; Glioblastoma; GBM; Grade IV Astrocytoma; Glioma; Brain Cancer; Brain Tumor
Intervention: Drug: Dendritic cell immunotherapy
Sponsors: Northwest Biotherapeutics; Northwest Biotherapeutics
Recruiting - verified May 2013
Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

Condition: HIV Infections
Interventions: Drug: Current ARV medications; Drug: Current TB medications; Drug: Current hormonal contraceptive medications
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified May 2013
Consent for Use of Stored Patient Specimens for Future Testing

Condition: HIV Infections
Intervention:
Sponsors: AIDS Clinical Trials Group; AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified June 2013
Prenatal and Postnatal Studies of Interventions for Prevention of Mother-To-Child Transmission

Conditions: HIV Infections; Pregnancy Complications, Infectious
Intervention: Behavioral: Adherence assessment
Sponsors: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; International Maternal Pediatric Adolescent AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified June 2013

Find Paid Research Studies in North Carolina

Welcome to Paid Research Studies.